CN117715907A - 10-取代-1-氮杂吩噻嗪衍生物及其应用 - Google Patents
10-取代-1-氮杂吩噻嗪衍生物及其应用 Download PDFInfo
- Publication number
- CN117715907A CN117715907A CN202180098067.1A CN202180098067A CN117715907A CN 117715907 A CN117715907 A CN 117715907A CN 202180098067 A CN202180098067 A CN 202180098067A CN 117715907 A CN117715907 A CN 117715907A
- Authority
- CN
- China
- Prior art keywords
- compound
- alkyl
- pharmaceutical composition
- group
- endometrial cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 10-substituted-1-azaphenothiazine Chemical class 0.000 title claims abstract description 38
- 206010014733 Endometrial cancer Diseases 0.000 claims abstract description 37
- 206010014759 Endometrial neoplasm Diseases 0.000 claims abstract description 37
- 239000003814 drug Substances 0.000 claims abstract description 16
- 125000001424 substituent group Chemical group 0.000 claims abstract description 4
- 150000001875 compounds Chemical class 0.000 claims description 58
- 238000000034 method Methods 0.000 claims description 55
- 238000002360 preparation method Methods 0.000 claims description 48
- 125000003118 aryl group Chemical group 0.000 claims description 20
- 239000008194 pharmaceutical composition Substances 0.000 claims description 15
- 150000003839 salts Chemical class 0.000 claims description 15
- 125000000623 heterocyclic group Chemical group 0.000 claims description 12
- 125000001072 heteroaryl group Chemical group 0.000 claims description 11
- 239000000583 progesterone congener Substances 0.000 claims description 8
- 238000011282 treatment Methods 0.000 claims description 8
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 6
- 125000005842 heteroatom Chemical group 0.000 claims description 6
- 229910052760 oxygen Inorganic materials 0.000 claims description 6
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 5
- 229910052717 sulfur Inorganic materials 0.000 claims description 5
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 4
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 4
- 239000003560 cancer drug Substances 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 claims description 3
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 3
- 229910052736 halogen Inorganic materials 0.000 claims description 3
- 150000002367 halogens Chemical class 0.000 claims description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 3
- 238000006467 substitution reaction Methods 0.000 claims description 3
- DOMWKUIIPQCAJU-LJHIYBGHSA-N Hydroxyprogesterone caproate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)CCCCC)[C@@]1(C)CC2 DOMWKUIIPQCAJU-LJHIYBGHSA-N 0.000 claims description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 125000004803 chlorobenzyl group Chemical group 0.000 claims description 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 229950000801 hydroxyprogesterone caproate Drugs 0.000 claims description 2
- 239000004615 ingredient Substances 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 238000010255 intramuscular injection Methods 0.000 claims description 2
- 239000007927 intramuscular injection Substances 0.000 claims description 2
- 238000010253 intravenous injection Methods 0.000 claims description 2
- 229960002985 medroxyprogesterone acetate Drugs 0.000 claims description 2
- PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 claims description 2
- 229960004296 megestrol acetate Drugs 0.000 claims description 2
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 claims description 2
- 239000006186 oral dosage form Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 238000011321 prophylaxis Methods 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 239000006211 transdermal dosage form Substances 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 24
- 206010028980 Neoplasm Diseases 0.000 abstract description 20
- 230000006907 apoptotic process Effects 0.000 abstract description 16
- 230000005764 inhibitory process Effects 0.000 abstract description 14
- 229940079593 drug Drugs 0.000 abstract description 12
- 230000015572 biosynthetic process Effects 0.000 abstract description 9
- 230000035755 proliferation Effects 0.000 abstract description 7
- 238000007920 subcutaneous administration Methods 0.000 abstract description 7
- 230000012010 growth Effects 0.000 abstract description 6
- 238000011580 nude mouse model Methods 0.000 abstract description 6
- 241000699660 Mus musculus Species 0.000 abstract description 5
- 238000013508 migration Methods 0.000 abstract description 5
- 230000005012 migration Effects 0.000 abstract description 5
- 238000002054 transplantation Methods 0.000 abstract description 5
- 238000001727 in vivo Methods 0.000 abstract description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 48
- ZAISDHPZTZIFQF-UHFFFAOYSA-N 2h-1,4-thiazine Chemical compound C1SC=CN=C1 ZAISDHPZTZIFQF-UHFFFAOYSA-N 0.000 description 46
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 46
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 30
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 25
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 24
- 241000699670 Mus sp. Species 0.000 description 23
- LIZKZVQBLDHKCY-UHFFFAOYSA-N 3-azaspiro[5.5]undecane Chemical compound C1CCCCC21CCNCC2 LIZKZVQBLDHKCY-UHFFFAOYSA-N 0.000 description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- 238000006243 chemical reaction Methods 0.000 description 17
- 239000007787 solid Substances 0.000 description 16
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
- NKBWMBRPILTCRD-UHFFFAOYSA-N 2-Methylheptanoic acid Chemical compound CCCCCC(C)C(O)=O NKBWMBRPILTCRD-UHFFFAOYSA-N 0.000 description 12
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 230000002829 reductive effect Effects 0.000 description 12
- 239000012065 filter cake Substances 0.000 description 11
- 239000002994 raw material Substances 0.000 description 11
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 10
- 238000001914 filtration Methods 0.000 description 10
- 239000000463 material Substances 0.000 description 10
- 238000001543 one-way ANOVA Methods 0.000 description 10
- WJZIPMQUKSTHLV-UHFFFAOYSA-N 2-ethyldecanoic acid Chemical compound CCCCCCCCC(CC)C(O)=O WJZIPMQUKSTHLV-UHFFFAOYSA-N 0.000 description 9
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 9
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 9
- 239000002609 medium Substances 0.000 description 9
- 238000003235 crystal violet staining Methods 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- 239000007858 starting material Substances 0.000 description 8
- 125000002947 alkylene group Chemical group 0.000 description 7
- YRCGAHTZOXPQPR-UHFFFAOYSA-N 2-ethylnonanoic acid Chemical compound CCCCCCCC(CC)C(O)=O YRCGAHTZOXPQPR-UHFFFAOYSA-N 0.000 description 6
- YSEQNZOXHCKLOG-UHFFFAOYSA-N 2-methyl-octanoic acid Chemical compound CCCCCCC(C)C(O)=O YSEQNZOXHCKLOG-UHFFFAOYSA-N 0.000 description 6
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 108010040476 FITC-annexin A5 Proteins 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- 125000004432 carbon atom Chemical group C* 0.000 description 6
- 229960004316 cisplatin Drugs 0.000 description 6
- 239000012043 crude product Substances 0.000 description 6
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 6
- 238000001704 evaporation Methods 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000012544 monitoring process Methods 0.000 description 5
- 238000011002 quantification Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 238000005160 1H NMR spectroscopy Methods 0.000 description 4
- KUSYIGBGHPOWEL-UHFFFAOYSA-N 2-methyl nonaoic acid Chemical compound CCCCCCCC(C)C(O)=O KUSYIGBGHPOWEL-UHFFFAOYSA-N 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 4
- 229930040373 Paraformaldehyde Natural products 0.000 description 4
- 210000003169 central nervous system Anatomy 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000004440 column chromatography Methods 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 238000007603 infrared drying Methods 0.000 description 4
- 230000033001 locomotion Effects 0.000 description 4
- 229920002866 paraformaldehyde Polymers 0.000 description 4
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- IBODDUNKEPPBKW-UHFFFAOYSA-N 1,5-dibromopentane Chemical compound BrCCCCCBr IBODDUNKEPPBKW-UHFFFAOYSA-N 0.000 description 3
- SAOSCTYRONNFTC-UHFFFAOYSA-N 2-methyl-decanoic acid Chemical compound CCCCCCCCC(C)C(O)=O SAOSCTYRONNFTC-UHFFFAOYSA-N 0.000 description 3
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 3
- 108010087230 Sincalide Proteins 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- 230000003698 anagen phase Effects 0.000 description 3
- 238000010609 cell counting kit-8 assay Methods 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 3
- 229960001076 chlorpromazine Drugs 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 125000001183 hydrocarbyl group Chemical group 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000003208 petroleum Substances 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 3
- DYWSVUBJGFTOQC-UHFFFAOYSA-N xi-2-Ethylheptanoic acid Chemical compound CCCCCC(CC)C(O)=O DYWSVUBJGFTOQC-UHFFFAOYSA-N 0.000 description 3
- UKDZROJJLPDLDO-UHFFFAOYSA-N 10h-pyrido[3,2-b][1,4]benzothiazine Chemical compound C1=CN=C2NC3=CC=CC=C3SC2=C1 UKDZROJJLPDLDO-UHFFFAOYSA-N 0.000 description 2
- UUOLETYDNTVQDY-UHFFFAOYSA-N 2-chloro-3-nitropyridine Chemical compound [O-][N+](=O)C1=CC=CN=C1Cl UUOLETYDNTVQDY-UHFFFAOYSA-N 0.000 description 2
- DMUXSGAKEXSNGN-UHFFFAOYSA-N 2-ethyloctanoic acid Chemical compound CCCCCCC(CC)C(O)=O DMUXSGAKEXSNGN-UHFFFAOYSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- RHQDFWAXVIIEBN-UHFFFAOYSA-N Trifluoroethanol Chemical compound OCC(F)(F)F RHQDFWAXVIIEBN-UHFFFAOYSA-N 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- 235000011114 ammonium hydroxide Nutrition 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000001640 apoptogenic effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 230000012292 cell migration Effects 0.000 description 2
- 230000003021 clonogenic effect Effects 0.000 description 2
- 230000005757 colony formation Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000035558 fertility Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000001794 hormone therapy Methods 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 125000003367 polycyclic group Chemical group 0.000 description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- RSJKGSCJYJTIGS-UHFFFAOYSA-N undecane Chemical compound CCCCCCCCCCC RSJKGSCJYJTIGS-UHFFFAOYSA-N 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 description 1
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 description 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 1
- ULTHEAFYOOPTTB-UHFFFAOYSA-N 1,4-dibromobutane Chemical compound BrCCCCBr ULTHEAFYOOPTTB-UHFFFAOYSA-N 0.000 description 1
- SGRHVVLXEBNBDV-UHFFFAOYSA-N 1,6-dibromohexane Chemical compound BrCCCCCCBr SGRHVVLXEBNBDV-UHFFFAOYSA-N 0.000 description 1
- JQZAEUFPPSRDOP-UHFFFAOYSA-N 1-chloro-4-(chloromethyl)benzene Chemical compound ClCC1=CC=C(Cl)C=C1 JQZAEUFPPSRDOP-UHFFFAOYSA-N 0.000 description 1
- FRPZMMHWLSIFAZ-UHFFFAOYSA-N 10-undecenoic acid Chemical compound OC(=O)CCCCCCCCC=C FRPZMMHWLSIFAZ-UHFFFAOYSA-N 0.000 description 1
- DCDGCHXHDAWBFH-UHFFFAOYSA-N 2,8-diazaspiro[4.5]decane-1,3-dione;hydrochloride Chemical compound Cl.O=C1NC(=O)CC11CCNCC1 DCDGCHXHDAWBFH-UHFFFAOYSA-N 0.000 description 1
- NJWIMFZLESWFIM-UHFFFAOYSA-N 2-(chloromethyl)pyridine Chemical compound ClCC1=CC=CC=N1 NJWIMFZLESWFIM-UHFFFAOYSA-N 0.000 description 1
- MVTRQRSNYWDWMY-UHFFFAOYSA-N 2-amino-4-(trifluoromethyl)benzenethiol Chemical compound NC1=CC(C(F)(F)F)=CC=C1S MVTRQRSNYWDWMY-UHFFFAOYSA-N 0.000 description 1
- KIDLBEYNOGVICH-UHFFFAOYSA-N 2-amino-4-methoxybenzenethiol Chemical compound COC1=CC=C(S)C(N)=C1 KIDLBEYNOGVICH-UHFFFAOYSA-N 0.000 description 1
- VRVRGVPWCUEOGV-UHFFFAOYSA-N 2-aminothiophenol Chemical class NC1=CC=CC=C1S VRVRGVPWCUEOGV-UHFFFAOYSA-N 0.000 description 1
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 108050005848 Annexin A10 Proteins 0.000 description 1
- 238000011729 BALB/c nude mouse Methods 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 101100391174 Dictyostelium discoideum forC gene Proteins 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 1
- VQTUBCCKSQIDNK-UHFFFAOYSA-N Isobutene Chemical group CC(C)=C VQTUBCCKSQIDNK-UHFFFAOYSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- KCXMKQUNVWSEMD-UHFFFAOYSA-N benzyl chloride Chemical compound ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 description 1
- 229940073608 benzyl chloride Drugs 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 229940114081 cinnamate Drugs 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 229940120124 dichloroacetate Drugs 0.000 description 1
- GJYVZUKSNFSLCL-UHFFFAOYSA-N dichloromethanol Chemical compound OC(Cl)Cl GJYVZUKSNFSLCL-UHFFFAOYSA-N 0.000 description 1
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 1
- 125000004655 dihydropyridinyl group Chemical group N1(CC=CC=C1)* 0.000 description 1
- 125000005057 dihydrothienyl group Chemical group S1C(CC=C1)* 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000000431 effect on proliferation Effects 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 229940049906 glutamate Drugs 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N glutaric acid Chemical compound OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 125000004836 hexamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000005980 hexynyl group Chemical group 0.000 description 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 1
- 201000008980 hyperinsulinism Diseases 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- SNMVRZFUUCLYTO-UHFFFAOYSA-N n-propyl chloride Chemical compound CCCCl SNMVRZFUUCLYTO-UHFFFAOYSA-N 0.000 description 1
- YZMHQCWXYHARLS-UHFFFAOYSA-N naphthalene-1,2-disulfonic acid Chemical compound C1=CC=CC2=C(S(O)(=O)=O)C(S(=O)(=O)O)=CC=C21 YZMHQCWXYHARLS-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 125000004817 pentamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 125000005981 pentynyl group Chemical group 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000000079 pharmacotherapeutic effect Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229940095055 progestogen systemic hormonal contraceptives Drugs 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 238000012342 propidium iodide staining Methods 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 238000004537 pulping Methods 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 229940043131 pyroglutamate Drugs 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000010825 rotarod performance test Methods 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 229940116351 sebacate Drugs 0.000 description 1
- CXMXRPHRNRROMY-UHFFFAOYSA-L sebacate(2-) Chemical compound [O-]C(=O)CCCCCCCCC([O-])=O CXMXRPHRNRROMY-UHFFFAOYSA-L 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 125000003003 spiro group Chemical group 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 229940114926 stearate Drugs 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- UXAWXZDXVOYLII-HTQZYQBOSA-N tert-butyl (1r,4r)-2,5-diazabicyclo[2.2.1]heptane-2-carboxylate Chemical compound C1[C@H]2N(C(=O)OC(C)(C)C)C[C@@H]1NC2 UXAWXZDXVOYLII-HTQZYQBOSA-N 0.000 description 1
- UXAWXZDXVOYLII-YUMQZZPRSA-N tert-butyl (1s,4s)-2,5-diazabicyclo[2.2.1]heptane-2-carboxylate Chemical compound C1[C@@H]2N(C(=O)OC(C)(C)C)C[C@H]1NC2 UXAWXZDXVOYLII-YUMQZZPRSA-N 0.000 description 1
- JXQPSCYGAWSTQP-UHFFFAOYSA-N tert-butyl 1,7-diazaspiro[3.5]nonane-7-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC11NCC1 JXQPSCYGAWSTQP-UHFFFAOYSA-N 0.000 description 1
- AGYJKDRKBSJWLJ-UHFFFAOYSA-N tert-butyl 1,8-diazaspiro[4.5]decane-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCC11CCNCC1 AGYJKDRKBSJWLJ-UHFFFAOYSA-N 0.000 description 1
- UZPDXRXHTUSGLN-UHFFFAOYSA-N tert-butyl 1,8-diazaspiro[4.5]decane-8-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC11NCCC1 UZPDXRXHTUSGLN-UHFFFAOYSA-N 0.000 description 1
- FRROFBJYHIEDPS-UHFFFAOYSA-N tert-butyl 1-oxa-4,9-diazaspiro[5.5]undecane-9-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC21OCCNC2 FRROFBJYHIEDPS-UHFFFAOYSA-N 0.000 description 1
- KVOUHLVOTMOJBS-UHFFFAOYSA-N tert-butyl 2,6-diazaspiro[3.3]heptane-2-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CC11CNC1 KVOUHLVOTMOJBS-UHFFFAOYSA-N 0.000 description 1
- BGUYAMZPJMTFRU-UHFFFAOYSA-N tert-butyl 2,6-diazaspiro[3.4]octane-6-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCC11CNC1 BGUYAMZPJMTFRU-UHFFFAOYSA-N 0.000 description 1
- UJIOQJJFPYXAEM-UHFFFAOYSA-N tert-butyl 2,7-diazaspiro[3.4]octane-2-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CC21CNCC2 UJIOQJJFPYXAEM-UHFFFAOYSA-N 0.000 description 1
- HWLNKJXLGQVMJH-UHFFFAOYSA-N tert-butyl 2,7-diazaspiro[3.5]nonane-2-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CC21CCNCC2 HWLNKJXLGQVMJH-UHFFFAOYSA-N 0.000 description 1
- NRADOPGBTAJXKB-UHFFFAOYSA-N tert-butyl 2,7-diazaspiro[3.5]nonane-7-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC11CNC1 NRADOPGBTAJXKB-UHFFFAOYSA-N 0.000 description 1
- HPPARSNAMZJAPZ-UHFFFAOYSA-N tert-butyl 2,7-diazaspiro[4.4]nonane-2-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCC11CNCC1 HPPARSNAMZJAPZ-UHFFFAOYSA-N 0.000 description 1
- NFNCPNAVNRBDOU-UHFFFAOYSA-N tert-butyl 2,8-diazaspiro[4.5]decane-2-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCC21CCNCC2 NFNCPNAVNRBDOU-UHFFFAOYSA-N 0.000 description 1
- MGHFVXFMQGQAKJ-UHFFFAOYSA-N tert-butyl 2,8-diazaspiro[4.5]decane-8-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC11CNCC1 MGHFVXFMQGQAKJ-UHFFFAOYSA-N 0.000 description 1
- UTFBOGXIVNMTCO-UHFFFAOYSA-N tert-butyl 2,9-diazaspiro[5.5]undecane-2-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCCC11CCNCC1 UTFBOGXIVNMTCO-UHFFFAOYSA-N 0.000 description 1
- OUFBVDKNEWUFHP-UHFFFAOYSA-N tert-butyl 3,6-diazabicyclo[3.1.1]heptane-6-carboxylate Chemical compound C1C2N(C(=O)OC(C)(C)C)C1CNC2 OUFBVDKNEWUFHP-UHFFFAOYSA-N 0.000 description 1
- 125000004853 tetrahydropyridinyl group Chemical group N1(CCCC=C1)* 0.000 description 1
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M trans-cinnamate Chemical compound [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- PZMFITAWSPYPDV-UHFFFAOYSA-N undecane-2,4-dione Chemical compound CCCCCCCC(=O)CC(C)=O PZMFITAWSPYPDV-UHFFFAOYSA-N 0.000 description 1
- 229940075466 undecylenate Drugs 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
一种10‑取代‑1‑氮杂吩噻嗪衍生物及其应用，该衍生物结构如式(I)所示，各取代基的定义如说明书和权利要求书所述。本发明的10‑取代‑1‑氮杂吩噻嗪衍生物对子宫内膜癌细胞具有显著增殖抑制作用，能够抑制子宫内膜癌细胞的克隆形成和迁移，诱导子宫内膜癌细胞凋亡，以及体内抑制裸鼠皮下移植瘤的生长。因此，本发明提供的10‑取代‑1‑氮杂吩噻嗪衍生物有望被用于制备治疗和/或预防子宫内膜癌药物。
Description
本发明涉及药物化学和药物治疗学领域，具体涉及10-取代-1-氮杂吩噻嗪衍生物及其制备方法和用途。
子宫内膜癌(Endometrial Cancer，EC)是发生于子宫内膜的一组上皮性恶性肿瘤，是世界上最常见的妇科恶性肿瘤之一，其发病率和死亡率都在上升。虽然EC在绝经后妇女中更常见，但在过去的十年，年轻女性EC的发病率急剧增加，有越来越年轻的女性被诊断出子宫内膜癌，发病率增加的根本原因是肥胖的流行和由此引起的高胰岛素血症，随着肥胖率的上升，子宫内膜癌的发病率也在上升。2015年中国新增EC病例约63400例，新增EC死亡病例约21,800例。
EC通常分为I型和II型，两者主要区别是在于I型EC孕激素受体表达呈阳性，II型EC孕激素受体表达呈阴性。目前手术治疗是治疗EC的常用方法，但是对于需要保留生育功能的患者需要采用保守治疗方法，保守治疗的主要方法是应用孕激素类药物的激素疗法。然而激素疗法存在局限性，它只对孕激素受体表达呈阳性的患者有效并且复发率高，易产生耐药性。随着二胎、三胎政策的全面开放，年轻EC患者对保留生育功能的保守治疗需求增加。因此，开发新的EC治疗药物迫在眉睫。
发明内容
本发明的目的在于，提供一类EC治疗药物。
本发明另一个目的在于提供上述化合物在制备治疗和/或改善子宫内膜癌药物中的应用。
本发明的第一方面，提供一种式I所示化合物、或其立体异构体或药学上可接受的盐，
其中，n为2、3、4、5或6；
R
1为H、羟基、卤素、C
1-C
6烷基、C
1-C
6卤代烷基、C
1-C
6烷氧基、硝基、亚硝基、氨基、甲酰基、乙酰基或氰基；
R
2为取代或未取代的6-14元杂环基，所述杂环基含有选自下组的1、2、3或4个杂原子：N、O、S；所述取代是指具有一个或多个选自下组的取代基：-COOC
1-C
6烷基、-C
1-C
6亚烷基C
6-C
10芳基、氧代(＝O)、C
1-C
6烷基、C
1-C
6卤代烷基、C
2-C
6烯基、C
2-C
6炔基、-COC
1-C
6 烷基、-C
1-C
6亚烷基5-7元杂芳基、C
6-C
10芳基、5-7元杂芳基、-C
1-C
6亚烷基卤代C
6-C
10芳基、C
3-C
8环烷基。
在另一优选例中，R
1为H、羟基、F、Cl、Br、甲基、乙基、正丙基、异丙基、C
1-C
4氟代烷基、甲氧基、乙氧基。
在另一优选例中，R
2为取代或未取代的7-12元螺杂环基或桥杂环基，所述螺杂环基或桥杂环基含有选自下组的1、2或3个杂原子：N、O；所述取代是指具有1、2、3或4个选自下组的取代基：-COOC
1-C
4烷基、-C
1-C
2亚烷基苯基、氧代(＝O)、C
1-C
4烷基、C
1-C
4卤代烷基、C
2-C
4烯基、C
2-C
4炔基、-COC
1-C
4烷基、-C
1-C
2亚烷基5-7元杂芳基、C
6-C
10芳基、5-7元杂芳基、-C
1-C
2亚烷基卤代C
6-C
10芳基、C
3-C
6环烷基。
在另一优选例中，所述螺杂环基为
s
1、s
2、s
3、s
4各自独立地为1、2或3；Z为CH
2或NH。
在另一优选例中，所述桥杂环基为
n
1、n
2、n
3、n
4各自独立地为0、1、2或3。
在另一优选例中，R
2为式I-2或者I-3，
A
1、A
2、A
3、A
4各自独立地选自：N、O、S、-CO(CH
2)
p-、-(CH
2)
m-、-(CH
2)
mO-、-(CH
2)
mS-；m、p各自独立地为0、1、2或3；
X为CH、N或O；
n
1、n
2、n
3、n
4各自独立地为0、1、2或3；
R
3为H、-COOC
1-C
6烷基、-C
1-C
6亚烷基C
6-C
10芳基、C
1-C
6烷基、C
1-C
6卤代烷基、C
2-C
6烯基、C
2-C
6炔基、-COC
1-C
6烷基、-C
1-C
6亚烷基5-7元杂芳基、C
6-C
10芳基、5-7元杂芳基、-C
1-C
6亚烷基卤代C
6-C
10芳基、C
3-C
8环烷基。
在另一优选例中，R
3为H、叔丁氧羰基、C
1-C
4烷基、氯代苄基、苄基、-CH
2-6元含 氮杂芳基、-COC
1-C
4烷基或C
2-C
4炔基。
在另一优选例中，所述化合物选自下组：
本发明的第二方面，提供一种药物组合物，包括：
(1)第一方面所述的化合物、或其药学上可接受的盐、或其立体异构体；和(2)药学上可接受的载体。
在另一优选例中，所述药物组合物还包括其他药学上可接受的成分为抗子宫内膜癌药物。在另一优选例中，所述抗子宫内膜癌药物为孕激素。在另一优选例中，所述孕激素为醋酸甲地孕酮、酸酸甲羟孕酮或己酸孕酮中的一种或两种以上的组合。
在另一优选例中，所述药物组合物为注射剂、片剂、胶囊剂、丸剂、悬浮剂或乳剂。
在另一优选例中，所述药物组合物为口服剂型、经皮剂型、静脉或肌肉注射剂型。
本发明的第三方面，提供第一方面所述的化合物或其立体异构体，或其药学上可接受的盐或第二方面所述的药物组合物的用途，用于制备治疗和/或预防子宫内膜癌的药物。
本发明第四方面提供了第一方面所述的化合物或其立体异构体，或其药学上可接受的盐的制备方法，具体合成策略如下：
所述方法具体步骤如下：
1)将不同4位取代或未取代的2-氨基苯硫酚溶于乙腈中，冰浴下慢慢加入叔丁醇钾，搅拌30min后慢慢加入2-氯-3-硝基吡啶，移到室温反应2h，过滤，保留滤饼，滤液减压蒸除溶剂，剩余残渣用乙醇溶解，过滤，合并滤饼，在红外干燥箱中干燥过夜，得中间体II
A(II
B或II
C)。
2)在圆底烧瓶中加入中间体II
A(II
B或II
C)、醋酸酐和吡啶室温反应过液，过滤，保留滤饼，滤液加入水析出产物，过滤，合并滤饼，放入红外干燥箱，约90℃干燥过夜，得中间体III
A(III
B或III
C)。
3)在圆底烧瓶中加入中间体III
A(III
B或III
C)、丙酮、KOH和乙醇，60℃左右反应2h，柱层析纯化(石油醚：乙酸乙酯＝10:1)，得中间体Ⅳ
A(Ⅳ
B或Ⅳ
C)。
4)在圆底烧瓶中加入中间体Ⅳ
A(Ⅳ
B或Ⅳ
C)、浓盐酸和乙醇，80℃左右反应过夜，减压蒸除溶剂，加氨水过滤得淡黄色固体中间体Ⅴ
A(Ⅴ
B或Ⅴ
C)。
5)中间体Ⅴ
A(Ⅴ
B或Ⅴ
C或10H-吡啶并(3,2-b)(1,4)苯并噻嗪)分别与不同链长的二溴烷反应得中间体Ⅵ
A(ⅤI
B或ⅤI
C或ⅤI
D或ⅤI
E或ⅤI
F)。
6)关键中间体Ⅵ
A(ⅤI
B或ⅤI
C或ⅤI
D或ⅤI
E或ⅤI
F)分别与不同胺反应得到不同衍生物X01-19、X27-35。
7)在X02中加入三氟乙酸和二氯甲烷，室温反应2小时得X19，随后X19分别与不同的R
3Cl反应，加入K
2CO
3和乙腈，60℃回流过夜，得不同衍生物X20-26。
本发明的第五方面，提供一种治疗子宫内膜癌的方法，包括向有需要的对象施用第一方面所述的化合物、或其药学上可接受的盐、或其立体异构体。
应理解，在本发明范围内中，本发明的上述各技术特征和在下文(如实施例)中具体描述的各技术特征之间都可以互相组合，从而构成新的或优选的技术方案。说明书中所揭示的各个特征，可以被任何提供相同、均等或相似目的的替代性特征取代。限于篇幅，在此不再一一累述。
图1为化合物X32对ISK和KLE细胞克隆形成的影响示意图。(A)ISK细胞结晶紫染色；(B)KLE细胞结晶紫染色；(C)ISK细胞结晶紫染色定量；(D)KLE细胞结晶紫染色定量；数据为平均值±SD，*p<0.05,**p<0.01,***p<0.001,****p<0.0001vs Ctrl,One-way ANOVA.
图2为化合物X32对ISK和KLE细胞的迁移能力的影响示意图。(A)ISK细胞结晶紫染色；(B)ISK细胞结晶紫染色定量；(C)KLE细胞结晶紫染色；(D)KLE细胞结晶紫染色定量；数据为平均值±SD，*p<0.05,**p<0.01,***p<0.001,****p<0.0001vs Ctrl,One-way ANOVA.
图3为化合物X32对ISK和KLE细胞的凋亡的影响示意图。(A)对ISK细胞凋亡的影响；(B)对KLE细胞凋亡的影响；(C)ISK细胞凋亡比例定量；(D)KLE细胞凋亡比例定量；数据为平均值±SD，*p<0.05,**p<0.01,***p<0.001,****p<0.0001vs Ctrl,One-way ANOVA.
图4为化合物X32对小鼠中枢神经***的影响示意图。数据为平均值±SEM，*p<0.05,**p<0.01,***p<0.001,****p<0.0001vs Vehicle,one-way ANOVA.
图5为化合物X01对小鼠皮下KLE细胞移植瘤的生长抑制作用示意图。(A)小鼠体重随给药时间的变化曲线；(B)给药14天后肿瘤体积；(C)给药14天后小鼠肿瘤图片；(D)给药14天后肿瘤重量；数据为平均值±SEM，*p<0.05,**p<0.01,***p<0.001,****p<0.0001vs Vehicle,one-way ANOVA.
本申请的发明人经过广泛而深入的研究，发现了一类具有抗子宫内膜癌活性的10-取代-1-氮杂吩噻嗪衍生物，其对EC细胞具有显著增殖抑制作用，能够抑制EC细胞的克隆形成和迁移，诱导EC细胞凋亡，以及体内抑制裸鼠皮下移植瘤的生长。在此基础上，完成了本发明。
术语
在本发明中采用的术语具有以下含义。
在本发明中，术语“C
1-C
6”是指具有1、2、3、4、5或6个碳原子，“C
1-C
8”是指具有1、2、3、4、5、6、7或8个碳原子，依此类推。“5-7元”是指具有5、6或7个环原子，依此类推。
“烷基”是指直链或支链烷基，如甲基、乙基、正丙基、异丙基、正丁基、仲丁基、异丁基、叔丁基等。
“亚烷基”是指具有指定的碳原子数并连接至少两个其他基团的直链或支链饱和脂肪族基团，即二价烃基团。连接到亚烷基的两个基团可以连接到亚烷基上相同的或不同原子。例如，直链亚烷基可以是-(CH
2)q-的二价基团，其中q是1、2、3、4、5或6。代表性的亚烷基包括但不限于亚甲基、亚乙基、亚丙基、亚异丙基、亚丁基、亚异丁基、亚仲丁基、亚戊基和亚己基。
术语“烷氧基”表示-O-(C
1-
6烷基)基团。例如术语“C
1-C
6烷氧基”是指具有1至6个碳原子的直链或支链烷氧基，非限制性地包括甲氧基、乙氧基、正丙氧基、异丙氧基和丁氧基等。
术语“烯基”表示包含至少一个双键的直链或支链烃基部分，例如术语“C
2-C
6烯基”是指具有2至6个碳原子的含有一个双键的直链或支链烯基，非限制性地包括乙烯基、丙烯基、丁烯基、异丁烯基、戊烯基和己烯基等。
术语“炔基”是指含有一个三键的直链或支链炔基，非限制性地包括乙炔基、丙炔基、丁炔基、异丁炔基、戊炔基和己炔基等。
“环烷基”是指表示饱和的环状烃基部分，如环丙基、环丁基、环戊基、环己基、环庚基等。
术语“芳基”表示包含一个或多个芳环的烃基部分。例如术语“C
6-C
10芳基”是指在环上不含杂原子的具有6至10个碳原子的芳香族环基，如苯基、萘基等。
在本发明中，术语“杂芳基”表示包含至少一个(如1、2、3或4个)环杂原子(例如N，O或S)的芳香性的环状基团，如吡咯基、呋喃基、噻吩基、吡唑基、恶唑基、吡啶基、嘧啶基等。
术语“杂环基”表示包含至少一个(如1、2、3或4个)环杂原子(例如N，O或S)的饱和或不饱和的、非芳香性的环状基团，例如四氢吡啶基、吡咯啉基、二氢吡啶基、二氢呋喃基、二氢噻吩基、吗啉基。杂环基可以是单环杂环、多环杂环，多环杂环基包括螺环、稠环和桥环。
“卤素”是F、Cl、Br或I。
本发明还包括上述化合物药学上可接受的盐。本发明10-取代-1-氮杂吩噻嗪衍生物的药用盐是指能够保留游离碱的生物有效性而无其它副作用的，与无机酸或有机酸所形成的盐。无机酸盐包括但不限于盐酸盐、氢溴酸盐、硫酸盐、硝酸盐、磷酸盐等；有机酸盐包括但不限于甲酸盐、乙酸盐、2,2-二氯乙酸盐、三氟乙酸盐、丙酸盐、己酸盐、辛酸盐、癸酸盐、十一碳烯酸盐、乙醇酸盐、葡糖酸盐、乳酸盐、癸二酸盐、己二酸盐、戊二酸盐、丙二酸盐、草酸盐、马来酸盐、琥珀酸盐、富马酸盐、酒石酸盐、柠檬酸盐、棕榈酸盐、硬脂酸盐、油酸盐、肉桂酸盐、月桂酸盐、苹果酸盐、谷氨酸盐、焦谷氨酸盐、天冬氨酸盐、苯甲酸盐、甲磺酸盐、苯磺酸盐、对甲苯磺酸盐、海藻酸盐、抗坏血酸盐、水杨酸盐、4-氨基水杨酸盐、萘二磺酸盐等。这些盐可通过已知的成盐方法由式I的化合物制备。
在以下的实施例中将进一步举例说明本发明。这些实施例仅用于说明本发明，但不以任何方式限制本发明的保护范围。以下实施例中所用的实验材料和试剂如无特别说明均可从市售渠道获得。
实施例1中间体II
A、Ⅱ
B、Ⅱ
C的制备
向干净的500mL反应瓶中依次加入乙腈200mL，20.0g 2-氨基-4-氯苯硫酚，冰浴下慢慢加入14.1g叔丁醇钾，搅拌30min，慢慢加入19.8g 2-氯-3-硝基吡啶，加毕移到室温，反应2h，TLC板监测反应完全，过滤，保留滤饼，滤液减压蒸除溶剂，剩余残渣用乙醇打浆，过滤，合并滤饼，放入红外干燥箱，约50℃干燥过夜，得到棕黄色固体为Ⅱ
A粗产品。
1H NMR(400MHz,Chloroform-d)δ8.55(dd,J＝3.9,1.9Hz,1H),8.51(dd,J＝8.2,1.8Hz,1H),7.38(d,J＝8.1Hz,1H),7.21(dd,J＝8.2,4.0Hz,1H),7.02(dd,J＝8.2,1.9 Hz,1H),6.96(d,J＝2.0Hz,1H).
具体实施步骤同Ⅱ
A的制备，不同之处在于原料2-氨基-4-氯苯硫酚换为2-氨基-4-甲氧基苯硫酚，得到土黄色絮状物为Ⅱ
B粗产品。
1H NMR(400MHz,DMSO-d
6)δ8.63–8.55(m,2H),7.37(dd,J＝8.2,4.6Hz,1H),7.14(d,J＝8.4Hz,1H),6.31(d,J＝2.7Hz,1H),6.19(dd,J＝8.5,2.7Hz,1H),5.35(s,2H),3.72(s,3H).
具体实施步骤同Ⅱ
A的制备，不同之处在于原料2-氨基-4-氯苯硫酚换为2-氨基-4-三氟甲基苯硫酚，得到土黄色固体为Ⅱ
C粗产品。
1H NMR(400MHz,DMSO-d6)δ8.66–8.54(m,2H),7.48(d,J＝7.9Hz,1H),7.42(dd,J＝8.2,4.7Hz,1H),7.02(d,J＝2.0Hz,1H),6.82(dd,J＝7.9,2.0Hz,1H),5.86(s,2H).
实施例2中间体Ⅲ
A、Ⅲ
B、Ⅲ
C的制备
向干净的250mL反应瓶中依次加入醋酸酐100mL，10.0g II
A，2.0mL吡啶，室温反应过液，TLC板监测反应完全，过滤，保留滤饼，滤液加入500mL水析出产物，过滤，合并滤饼，放入红外干燥箱，约90℃干燥过夜，得到黄色固体为Ⅲ
A粗产品。
1H NMR(400MHz,CDCl3)δ8.01(dd,J＝4.8,1.6Hz,1H),7.26(dd,J＝7.6,2.0Hz,1H),6.95(d,J＝8.0Hz,1H),6.90(dd,J＝8.4,2.0Hz,1H),6.83(d,J＝2.0Hz,1H),6.79–6.76(m,1H),4.11(t,J＝6.4Hz,2H),3.61(t,J＝6.4Hz,2H),1.97–1.91(m,4H).
具体实施步骤同IⅡ
A的制备，不同之处在于原料II
A换为II
B，得到黄色固体为IⅡ
B 粗产品。
1H NMR(400MHz,DMSO-d
6)δ9.03(s,1H),8.62(dd,J＝8.3,1.6Hz,1H),8.55(dd,J＝4.7,1.6Hz,1H),7.64–7.57(m,1H),7.48–7.37(m,2H),6.80(dd,J＝8.6,2.8Hz,1H),3.80(s,3H),1.90(s,3H).
具体实施步骤同IⅡ
A的制备，不同之处在于原料II
A换为II
C，得到黄色固体为IⅡ
C。
1H NMR(400MHz,DMSO-d
6)δ9.40(s,1H),8.66(dd,J＝8.2,1.6Hz,1H),8.55(dd,J＝4.7,1.6Hz,1H),8.30(d,J＝2.0Hz,1H),7.81(d,J＝8.1Hz,1H),7.55(dd,J＝8.0,2.0Hz,1H),7.47(dd,J＝8.3,4.6Hz,1H),1.90(s,3H).
实施例3中间体Ⅳ
A、Ⅳ
B、Ⅳ
C的制备
向干净的250mL反应瓶中依次加入丙酮100mL，10.0g IⅡ
A，5.2g KOH和1mL乙醇，升温至60℃左右，反应2h，TLC板监测反应完全，将反应体系降至室温，减压蒸除溶剂，剩余残渣柱层析纯化(石油醚：乙酸乙酯＝10:1)，得到黄色固体粗产品Ⅳ
A。
具体实施步骤同IV
A的制备，不同之处在于原料III
A换为III
B，得到黄色固体为Ⅳ
B。
1H NMR(400MHz,DMSO-d
6)δ8.50(dd,J＝4.8,1.7Hz,1H),8.12(dd,J＝7.8,1.7Hz,1H),7.97(d,J＝2.0Hz,1H),7.82(d,J＝8.2Hz,1H),7.68(dd,J＝8.4,2.0Hz,1H),7.45(dd,J＝7.9,4.8Hz,1H),3.75(s,3H),2.26(s,3H).
具体实施步骤同IV
A的制备，不同之处在于原料III
A换为III
C，得到黄色固体为Ⅳ
C。
1H NMR(400MHz,Chloroform-d)δ7.81(dd,J＝5.1,1.6Hz,1H),7.19(dd,J＝7.6,1.6Hz,1H),7.07(ddd,J＝8.1,1.8,0.8Hz,1H),7.00(d,J＝8.0Hz,1H),6.78–6.73(m,2H).
实施例4中间体Ⅴ
A、Ⅴ
B、Ⅴ
C的制备
向干净的250mL反应瓶中依次加入2gⅣ
A，60ml乙醇，2ml浓盐酸，升温至80℃左右，反应过夜，TLC板监测反应完全，将反应体系降至室温，减压蒸除溶剂，加氨水过滤得淡黄色固体Ⅴ
A。
1H NMR(400MHz,DMSO-d6)δ9.34(s,1H),7.83(dd,J＝4.9,1.6Hz,1H),7.30(dd,J＝7.6,1.6Hz,1H),6.94(d,J＝8.2Hz,1H),6.86(d,J＝2.2Hz,1H),6.82(dd,J＝8.2,2.2Hz,1H),6.76(dd,J＝7.5,4.9Hz,1H).
具体实施步骤同V
A的制备，不同之处在于原料IV
A换为IV
B，得到黄色固体为V
B。
1H NMR(400MHz,Chloroform-d)δ7.72(d,J＝5.3Hz,1H),7.66(s,1H),7.24–7.19(m,1H),6.82(d,J＝8.5Hz,1H),6.72(t,J＝6.4Hz,1H),6.46(d,J＝8.6Hz,1H),6.24(d,J＝2.5Hz,1H),3.75(s,3H).
具体实施步骤同V
A的制备，不同之处在于原料IV
A换为IV
C，得到黄色固体为V
C。
1H NMR(400MHz,Chloroform-d)δ7.81(dd,J＝5.1,1.6Hz,1H),7.19(dd,J＝7.6,1.6Hz,1H),7.07(ddd,J＝8.1,1.8,0.8Hz,1H),7.00(d,J＝8.0Hz,1H),6.79–6.70(m,2H).
实施例5中间体ⅤI
A、ⅤI
B、ⅤI
C、ⅤI
D、ⅤI
E、ⅤI
F的制备
向干净的100mL反应瓶中依次加入DMF 50mL，10.0g中间体V
A，20.1g1,5-二溴戊烷，5.1g氢氧化钾，室温反应1h，TLC板监测反应完全，加入150mL的水淬灭反应，乙酸乙酯萃取多次至水相没有产物点，合并有机相，饱和食盐水洗一次，无水硫酸钠 干燥，减压蒸除溶剂，剩余残渣柱层析纯化(石油醚：乙酸乙酯＝100:1，v/v)，得到灰黄色固体Ⅵ
A。
1H NMR(400MHz,CDCl3)δ8.01(dd,J＝4.8,1.6Hz,1H),7.24(dd,J＝7.2,1.6Hz,1H),6.93–6.85(m,3H),6.77(dd,J＝7.6,4.8Hz,1H),4.08(t,J＝7.6Hz,2H),2.34(t,J＝7.2Hz,2H),1.86–1.78(m,2H),1.65–1.58(m,4H).
具体实施步骤同Ⅵ
A的制备，不同之处在于原料V
A换为V
B，得到黄色固体为Ⅵ
B。
1H NMR(600MHz,Chloroform-d)δ8.01(s,1H),7.35–7.27(m,1H),6.96(d,J＝8.4Hz,1H),6.78(s,1H),6.47(d,J＝2.3Hz,2H),4.12(p,J＝6.5,5.9Hz,2H),3.79(s,3H),3.42(t,J＝6.8Hz,2H),1.92(dt,J＝15.0,6.9Hz,2H),1.84(q,J＝7.6Hz,2H),1.63–1.56(m,2H).
具体实施步骤同VI
A的制备，不同之处在于原料V
A换为V
C，得到黄色固体为Ⅵ
C。
1H NMR(400MHz,Chloroform-d)δ8.06(d,J＝4.9Hz,1H),7.34(d,J＝7.4Hz,1H),7.19(d,J＝8.0Hz,1H),7.14(d,J＝8.0Hz,1H),7.04(s,1H),6.86(dd,J＝7.4,4.9Hz,1H),4.19(t,J＝7.2Hz,2H),3.42(t,J＝6.7Hz,2H),1.96–1.87(m,2H),1.83(q,J＝7.5Hz,2H),1.61(dd,J＝10.4,5.0Hz,2H).
具体实施步骤同VI
A的制备，不同之处在于原料V
A换为10H-吡啶并(3,2-b)(1,4)苯并噻嗪，得到黄色固体为VI
D。
1H NMR(400MHz,Chloroform-d)δ7.99(d,J＝4.9Hz,1H),7.24(dd,J＝7.5,1.8Hz, 1H),7.14(t,J＝7.8Hz,1H),7.05(dd,J＝7.6,1.6Hz,1H),6.91(t,J＝7.5Hz,1H),6.84(d,J＝8.2Hz,1H),6.78–6.68(m,1H),4.10(q,J＝8.3Hz,2H),3.42(t,J＝6.7Hz,2H),1.88(dp,J＝35.3,7.3Hz,4H),1.60(q,J＝8.0Hz,2H).
具体实施步骤同Ⅵ
A的制备，不同之处在于原料1,5-二溴戊烷换为1,4-二溴丁烷，得到黄色油状物为Ⅵ
E。
1H NMR(400MHz,Chloroform-d)δ7.28(d,J＝3.5Hz,1H),6.98(d,J＝8.4Hz,2H),6.92(dd,J＝8.3,2.2Hz,1H),6.88–6.76(m,2H),4.13(t,J＝7.3Hz,2H),3.55–3.40(m,4H),2.04–1.95(m,2H).
具体实施步骤同Ⅵ
A的制备，不同之处在于原料1,5-二溴戊烷换为1,6-二溴已烷，得到黄色油状物为Ⅵ
F。
1H NMR(400MHz,Chloroform-d)δ8.01(dd,J＝5.0,1.7Hz,1H),7.26–7.22(m,1H),6.94(d,J＝8.1Hz,1H),6.88(dd,J＝8.2,2.0Hz,1H),6.82–6.74(m,2H),4.11–4.01(m,2H),3.56–3.37(m,2H),1.91–1.75(m,4H),1.49(dt,J＝8.9,5.3Hz,4H).
实施例6 10-(5-(3-氮杂螺环[5.5]十一碳-3-基)戊基)-8-氯-10H-苯并[b]吡啶[2,3-e][1,4]噻嗪(X01)的制备
向干净的50mL单口圆底烧瓶中依次加入15mL乙腈，200mg的中间体VI
A、87mg K
2CO
3，95mg 3-氮螺环[5,5]十一烷，60℃回流反应过夜，过滤减压蒸馏，柱层析 纯化(二氯甲醇：甲醇＝20：1，v/v)，得到黄色油状物X01。
1H NMR(400MHz,Chloroform-d)δ7.93(dd,J＝4.9,1.6Hz,1H),7.16(dd,J＝7.5,1.7Hz,1H),6.86(d,J＝8.1Hz,1H),6.80(dd,J＝8.2,1.9Hz,1H),6.74–6.67(m,2H),3.97(t,J＝7.3Hz,2H),2.36(t,6H),1.74(p,J＝7.4Hz,3H),1.46(m,6H),1.40–1.31(m,8H),1.25(m,J＝7.0Hz,4H).HRMS(ESI)m/z calcd for C
26H
34ClN
3S(M+H)
+456.2162,found 456.2242.
实施例7 9-(5-(8-氯-10H-苯并[b]吡啶[2,3-e][1,4]噻嗪-10-基)戊基)-3,9-二氮螺环[5.5]十一碳-3-羧酸叔丁酯(X02)的制备
具体实施步骤同实施例6，不同之处在于原料3-氮螺环[5,5]十一烷换为3-甲基-3,9-二氮杂螺[5,5]十一烷-3-甲酸叔丁酯，得到黄色油状物X02。
1H NMR(400MHz,Chloroform-d)δ8.00(dd,J＝5.0,1.7Hz,1H),7.24(d,J＝1.7Hz,1H),6.95(d,J＝8.2Hz,1H),6.88(dd,J＝8.2,1.9Hz,1H),6.80–6.75(m,2H),4.05(t,J＝7.1Hz,2H),3.37(t,J＝5.9Hz,4H),2.75(m,4H),1.83(m,J＝7.6Hz,8H),1.45(m,17H).HRMS(EI)m/z calcd for C
30H
41ClN
4O
2S(M
+)556.2639,found 556.2630.
实施例8 7-(5-(8-氯-10H-苯并[b]吡啶[2,3-e][1,4]噻嗪-10-基)戊基)-2,7-二氮螺环[4.4]壬烷-2-羧酸叔丁酯(X03)的制备
具体实施步骤同实施例6，不同之处在于原料3-氮螺环[5,5]十一烷换为2,7-二氮杂螺[4.4]壬烷-2-甲酸叔丁酯，得到黄色油状物X03。
1H NMR(400MHz,Chloroform-d)δ8.00(dd,J＝4.9,1.7Hz,1H),7.24(dd,J＝7.5,1.7Hz,1H),6.94(d,J＝8.2Hz,1H),6.88(dd,J＝8.2,1.9Hz,1H),6.80–6.75(m,2H),4.05(t,J＝7.2Hz,2H),3.44–3.22(m,5H),2.58(m,4H),1.94–1.77(m,6H),1.68(m,4H),1.46(m,11H).HRMS(EI)m/z calcd forC
28H
37ClN
4O
2S(M
+)528.2326,found 528.2322.
实施例9 8-(5-(8-氯-10H-苯并[b]吡啶[2,3-e][1,4]噻嗪-10-基)戊基)-2,8-二氮螺环[4.5]癸烷-2-羧酸叔丁酯(X04)的制备
具体实施步骤同实施例6，不同之处在于原料3-氮螺环[5,5]十一烷换为2,8-二氮杂螺[4.5]癸-2-羧酸叔丁酯，得到黄色油状物X04。
1H NMR(400MHz,Chloroform-d)δ8.00(dd,J＝4.9,1.7Hz,1H),7.24(dd,J＝7.5,1.7Hz,1H),6.94(d,J＝8.2Hz,1H),6.88(dd,J＝8.1,2.0Hz,1H),6.81–6.74(m,2H),4.05(t,J＝7.2Hz,2H),3.38(dt,J＝21.4,7.1Hz,2H),3.17(d,J＝33.0Hz,2H),1.90–1.55(m,13H),1.46(s,14H).HRMS(EI)m/z calcd for C
29H
39ClN
4O
2S(M
+)542.2842,found 542.2478.
实施例10 4-(5-(8-氯-10H-苯并[b]吡啶[2,3-e][1,4]噻嗪-10-基)戊基)-1-氧代-4,9-二氮螺环[5.5]十一碳-9-羧酸叔丁酯(X05)的制备
具体实施步骤同实施例6，不同之处在于原料3-氮螺环[5,5]十一烷换为1-氧杂-4,9-二氮杂螺[5.5]十一烷-9-甲酸叔丁酯，得到黄色油状物X05。
1H NMR(400MHz,Chloroform-d)δ8.00(dd,J＝4.9,1.7Hz,1H),7.25–7.21(m,1H),6.94(d,J＝8.1Hz,1H),6.88(dd,J＝8.2,1.9Hz,1H),6.81–6.74(m,2H),4.05(t,J＝7.2Hz,2H),3.70(m,4H),3.12(m,2H),2.43–2.07(m,6H),1.80(d,J＝7.5Hz,3H),1.62(m,3H),1.46(m,16H).HRMS(EI)m/z calcd for C
29H
39ClN
4O
3S(M
+)558.2431,found 558.2429.
实施例11 6-(5-(8-氯-10H-苯并[b]吡啶[2,3-e][1,4]噻嗪-10-基)戊基)-2,6-二氮螺环[3.4]辛烷-2-羧酸叔丁酯(X06)的制备
具体实施步骤同实施例6，不同之处在于原料3-氮螺环[5,5]十一烷换为2,6-二氮-螺[3.4]辛烷-2-碳酸叔丁酯，得到黄色油状物X06。
1H NMR(400MHz,Chloroform-d)δ8.00(dd,J＝4.9,1.7Hz,1H),7.24(dd,J＝7.5,1.7Hz,1H),6.94(d,J＝8.1Hz,1H),6.88(dd,J＝8.2,1.9Hz,1H),6.81–6.74(m,2H),4.04(t,J＝7.3Hz,2H),3.85(q,J＝8.6Hz,4H),2.70(d,J＝49.7Hz,4H),2.48(d,J＝7.8Hz,2H),2.07(t,J＝7.1Hz,2H),1.81(p,J＝7.4Hz,3H),1.60(t,J＝7.8Hz,3H),1.44(m,11H).HRMS(EI)m/z calcd for C
27H
35ClN
4O
2S(M
+)514.2169,found 514.2171.
实施例12 2-(5-(8-氯-10H-苯并[b]吡啶[2,3-e][1,4]噻嗪-10-基)戊基)-2,8-二氮螺环[4.5]癸烷-8-羧酸叔丁酯(X07)的制备
具体实施步骤同实施例6，不同之处在于原料3-氮螺环[5,5]十一烷换为2,8-二氮杂螺[4.5]癸烷-8-羧酸叔丁酯，得到黄色油状物X07。
1H NMR(400MHz,Chloroform-d)δ8.00(dd,J＝4.9,1.7Hz,1H),7.24(dd,J＝7.5,1.7Hz,1H),6.94(d,J＝8.2Hz,1H),6.88(dd,J＝8.2,2.0Hz,1H),6.81–6.74(m,2H),4.04(t,J＝7.2Hz,2H),3.41(dt,J＝11.3,5.4Hz,2H),3.35–3.26(m,2H),2.55(m,4H),1.81(p,J＝7.4Hz,12H),1.45(m,12H).HRMS(EI)m/z calcd for C
29H
39ClN
4O
2S(M
+)542.2482,found 542.2483.
实施例13 7-(5-(8-氯-10H-苯并[b]吡啶[2,3-e][1,4]噻嗪-10-基)戊基)-2,7-二氮螺环[3.5]壬烷-2-羧酸叔丁酯(X08)的制备
具体实施步骤同实施例6，不同之处在于原料3-氮螺环[5,5]十一烷换为2-叔丁氧羰基-2,7-二氮杂螺[3.5]壬烷，得到黄色油状物X08。
1H NMR(400MHz,Chloroform-d)δ8.00(dd,J＝4.9,1.7Hz,1H),7.23(dd,J＝7.5,1.7Hz,1H),6.93(d,J＝8.1Hz,1H),6.87(dd,J＝8.2,1.9Hz,1H),6.80–6.74(m,2H),4.03(t,J＝7.3Hz,2H),3.60(m,4H),2.35(m,4H),1.80(p,J＝7.4Hz,7H),1.44(m,14H).HRMS(EI)m/z calcd for C
28H
37ClN
4O
2S(M
+)528.2326,found 528.2323.
实施例14 2-(5-(8-氯-10H-苯并[b]吡啶[2,3-e][1,4]噻嗪-10-基)戊基)-2,7-二氮螺环[3.5]壬烷-7-羧酸叔丁酯(X09)的制备
具体实施步骤同实施例6，不同之处在于原料3-氮螺环[5,5]十一烷换为2,7-二氮杂螺[3.5]壬烷-7-甲酸叔丁酯，得到黄色油状物X09。
1H NMR(400MHz,Chloroform-d)δ8.00(dd,J＝4.9,1.7Hz,1H),7.24(dd,J＝7.5,1.7Hz,1H),6.94(d,J＝8.2Hz,1H),6.88(dd,J＝8.2,2.0Hz,1H),6.81–6.74(m,2H),4.04(t,J＝7.2Hz,2H),3.38–3.27(m,6H),2.77(t,J＝7.8Hz,2H),1.80(d,J＝7.1Hz,6H),1.60(q,J＝7.8Hz,2H),1.45(s,13H).HRMS(EI)m/z calcd for C
28H
37ClN
4O
2S(M
+)528.2326,found 528.2324.
实施例15 2-(5-(8-氯-10H-苯并[b]吡啶[2,3-e][1,4]噻嗪-10-基)戊基)-2,9-二氮螺环[5.5]十一碳-9-羧酸叔丁酯(X10)的制备
具体实施步骤同实施例6，不同之处在于原料3-氮螺环[5,5]十一烷换为2,9-二氮杂螺[5.5]十一烷-2-甲酸叔丁酯，得到黄色油状物X10。
1H NMR(400MHz,Chloroform-d)δ8.00(dd,J＝4.9,1.7Hz,1H),7.23(dd,J＝7.4,1.7Hz,1H),6.93(d,J＝8.2Hz,1H),6.87(dd,J＝8.2,2.0Hz,1H),6.81–6.73(m,2H),4.04(t,J＝7.3Hz,2H),3.34(m,4H),2.25(m,4H),1.80(p,J＝7.4Hz,2H),1.45(m,21H),1.28(m,J＝18.4Hz,2H).HRMS(EI)m/z calcd for C
30H
41ClN
4O
2S(M
+)556.2639,found 556.2635.
实施例16 6-(5-(8-氯-10H-苯并[b]吡啶[2,3-e][1,4]噻嗪-10-基)戊基)-2,6-二氮螺环[3.4]辛烷-2-羧酸叔丁酯(X11)的制备
具体实施步骤同实施例6，不同之处在于原料3-氮螺环[5,5]十一烷换为2,6-二氮-螺[3.4]辛烷-2-羧酸叔丁酯，得到黄色油状物X11。
1H NMR(400MHz,Chloroform-d)δ8.00(dd,J＝4.9,1.7Hz,1H),7.24(dd,J＝7.5,1.7Hz,1H),6.94(d,J＝8.2Hz,1H),6.88(dd,J＝8.1,1.9Hz,1H),6.80–6.74(m,2H),4.05(t,J＝7.3Hz,2H),3.93–3.79(m,5H),2.85–2.38(m,6H),2.15–2.02(m,2H),1.81(p,J＝7.4Hz,3H),1.44(d,J＝4.2Hz,13H).HRMS(EI)m/z calcd for C
27H
35ClN
4O
2S(M
+)514.2169,found 514.2163.
实施例17 8-(5-(8-氯-10H-苯并[b]吡啶[2,3-e][1,4]噻嗪-10-基)戊基)-1,8-二氮螺环[4.5]癸烷-1-羧酸叔丁酯(X12)的制备
具体实施步骤同实施例6，不同之处在于原料3-氮螺环[5,5]十一烷换为1,8-二氮杂-螺[4.5]癸烷-1-羧酸叔丁酯，得到黄色油状物X12。
1H NMR(400MHz,Chloroform-d)δ8.01(dd,J＝4.9,1.7Hz,1H),7.23(dd,J＝7.4,1.7Hz,1H),6.93(d,J＝8.2Hz,1H),6.87(dd,J＝8.2,2.0Hz,1H),6.82–6.72(m,2H),4.03(t,J＝7.3Hz,2H),3.42(m,2H),2.88(m,4H),1.92–1.67(m,8H),1.55–1.18(m,15H).HRMS(EI)m/z calcd for C
29H
39ClN
4O
2S(M
+)542.2482,found 542.2457.
实施例18 1-(5-(8-氯-10H-苯并[b]吡啶[2,3-e][1,4]噻嗪-10-基)戊基)-1,8-二氮螺环[4.5]癸烷-8-羧酸叔丁酯(X13)的制备
具体实施步骤同实施例6，不同之处在于原料3-氮螺环[5,5]十一烷换为1,8-二氮杂螺[4.5]癸烷-8-甲酸叔丁酯，得到黄色油状物X13。
1H NMR(400MHz,Chloroform-d)δ8.00(dd,J＝5.0,1.7Hz,1H),7.24(dd,J＝7.5,1.7Hz,1H),6.94(d,J＝8.2Hz,1H),6.88(dd,J＝8.1,1.9Hz,1H),6.81–6.74(m,2H),4.23–3.98(m,5H),2.74(s,4H),1.59(m,7H),1.46(m,13H),1.27(d,J＝12.4Hz,3H).HRMS(EI)m/z calcd for C
29H
39ClN
4O
2S(M
+)542.2482,found 542.2488.
实施例19 1-(5-(8-氯-10H-苯并[b]吡啶[2,3-e][1,4]噻嗪-10-基)戊基)-1,7-二氮螺环[3.5]壬烷-7-羧酸叔丁酯(X14)的制备
具体实施步骤同实施例6，不同之处在于原料3-氮螺环[5,5]十一烷换为1,7-二氮杂螺[3.5]壬烷-7-甲酸叔丁酯，得到黄色油状物X14。
1H NMR(400MHz,Chloroform-d)δ8.00(dd,J＝5.0,1.7Hz,1H),7.23(dd,J＝7.4,1.7Hz,1H),6.93(d,J＝8.2Hz,1H),6.87(dd,J＝8.2,2.0Hz,1H),6.81–6.73(m,2H),4.03(t,J＝7.3Hz,3H),2.67(d,J＝13.7Hz,3H),2.48(m,2H),1.97(m,3H),1.88–1.72(m,4H),1.59 (d,J＝17.8Hz,4H),1.45(m,15H).HRMS(EI)m/z calcd for C
28H
37ClN
4O
2S(M
+)528.2326,found 528.2328.
实施例20 2-(5-(8-氯-10H-苯并[b]吡啶[2,3-e][1,4]噻嗪-10-基)戊基)-2,6-二氮螺环[3.4]辛烷-6-羧酸叔丁酯(X15)的制备
具体实施步骤同实施例6，不同之处在于原料3-氮螺环[5,5]十一烷换为2,6-二氮杂螺[3.4]辛烷-6-甲酸叔丁酯，得到黄色油状物X15。
1H NMR(400MHz,Chloroform-d)δ8.00(dd,J＝4.9,1.7Hz,1H),7.24(dd,J＝7.5,1.7Hz,1H),6.94(d,J＝8.1Hz,1H),6.88(dd,J＝8.2,2.0Hz,1H),6.80–6.75(m,2H),4.04(t,J＝7.2Hz,2H),3.45(s,4H),3.33(d,J＝14.6Hz,5H),1.80(p,J＝7.3Hz,3H),1.45(s,17H).HRMS(EI)m/z calcd for C
27H
35ClN
4O
2S(M
+)514.2169,found 514.2164.
实施例21 6-(5-(8-氯-10H-苯并[b]吡啶[2,3-e][1,4]噻嗪-10-基)戊基)-2,6-二氮螺环[3.3]庚烷-2-羧酸叔丁酯(X16)的制备
具体实施步骤同实施例6，不同之处在于原料3-氮螺环[5,5]十一烷换为2,6-二氮杂螺[3.3]庚烷-2-甲酸叔丁酯，得到黄色油状物X16。
1H NMR(400MHz,Chloroform-d)δ8.00(d,J＝4.9Hz,1H),7.24(d,J＝7.4Hz,1H),6.94(d,J＝8.1Hz,1H),6.90–6.85(m,1H),6.80–6.73(m,2H),4.00(d,J＝18.7Hz,6H),3.30(s,4H),2.40(t,J＝6.7Hz,2H),1.79(q,J＝7.2Hz,2H),1.43(s,14H).HRMS(EI)m/z calcd for C
26H
33ClN
4O
2S(M
+)500.2013,found 500.2018.
实施例22 9-苄基-3-(5-(8-氯-10H-苯并[b]吡啶[2,3-e][1,4]噻嗪-10-基)戊基)-3,9-二氮螺环[5.5]十一烷-2,4-二酮(X17)的制备
具体实施步骤同实施例6，不同之处在于原料3-氮螺环[5,5]十一烷换为9-苄基-3,9-二杂氮[5.5]十一烷-2,4-二酮，得到黄色油状物X17。
1H NMR(400MHz,Chloroform-d)δ7.98(dd,J＝4.9,1.7Hz,1H),7.33(s,4H),7.21(dd,J＝7.5,1.7Hz,1H),6.91(d,J＝8.2Hz,1H),6.85(dd,J＝8.1,2.0Hz,1H),6.81–6.70(m,2H),4.01(t,J＝7.3Hz,2H),3.75(t,J＝7.5Hz,2H),3.57(m,2H),2.57(s,7H),1.79(p,J＝7.5Hz,2H),1.71–1.47(m,7H),1.45–1.21(m,4H).HRMS(EI)m/z calcd for C
32H
35ClN
4O
2S(M
+)574.2169,found 574.2159.
实施例23 8-(5-(8-氯-10H-苯并[b]吡啶[2,3-e][1,4]噻嗪-10-基)戊基)-2,8-二氮螺环[4.5]癸烷-1,3-二酮(X18)的制备
具体实施步骤同实施例6，不同之处在于原料3-氮螺环[5,5]十一烷换为2,8-二氮杂螺[4.5]癸烷-1,3-二酮盐酸盐，得到黄色油状物X18。
1H NMR(400MHz,DMSO-d
6)δ11.10(s,1H),8.05(dd,J＝4.9,1.7Hz,1H),7.46(dd,J＝7.5,1.7Hz,1H),7.12(d,J＝7.9Hz,1H),7.01(d,J＝7.9Hz,2H),6.91(dd,J＝7.5,4.8Hz,1H),4.06(t,J＝7.1Hz,2H),2.71(m,2H),2.23(m,2H),1.90–1.62(m,6H),1.56–1.15(m,8H).HRMS(EI)m/z calcd for C
24H
27ClN
4O
2S(M
+)470.1543,found 470.1541.
实施例24 10-(5-(3,9-二氮螺环[5.5]十一碳-3-基)戊基)-8-氯-10H-苯并[b]吡啶[2,3-e][1,4]噻嗪(X19)的制备
向干净的圆底烧瓶中加入200mg X02、10mL三氟乙酸和10mL二氯甲烷，室温反应2小时得黄色油状物X19。
1H NMR(400MHz,DMSO-d
6)δ10.52(s,1H),9.04(s,2H),8.07(dd,J＝4.9,1.5Hz,1H),7.49(dd,J＝7.6,1.6Hz,1H),7.14(d,J＝8.1Hz,1H),7.08–6.99(m,2H),6.93(dd,J＝7.5,4.9Hz,1H),4.06(d,J＝7.1Hz,3H),3.25(d,J＝12.5Hz,2H),3.00(dt,J＝12.0,5.7Hz,8H),1.86–1.61(m,10H),1.53(t,J＝5.8Hz,2H),1.40(p,J＝7.6Hz,2H).HRMS(ESI)m/z calcd for C
25H
33ClN
4S(M+H)
+457.2114,found 457.2170.
实施例25 8-氯-10-(5-(9-(丙-2-炔-1-基)-3,9-二氮螺环[5.5]十一碳-3-基)戊基)-10H苯并[b]吡啶[2,3-e][1,4]噻嗪(X20)的制备
向干净的圆底烧瓶中加入200mg X19、90mg 3-氯丙炔、120mg K
2CO
3和10mL乙腈，60℃回流过夜，得黄色油状物X20。
1H NMR(400MHz,Chloroform-d)δ8.00(dd,J＝4.9,1.7Hz,1H),7.24(dd,J＝7.4,1.7Hz,1H),6.94(d,J＝8.2Hz,1H),6.87(dd,J＝8.2,1.9Hz,1H),6.81–6.73(m,2H),4.04(t,J＝7.3Hz,2H),3.31(d,J＝2.4Hz,2H),2.50(q,J＝12.4,9.0Hz,9H),2.24(t,J＝2.4Hz,1H),1.81(p,J＝7.5Hz,3H),1.55(d,J＝11.1Hz,10H),1.49–1.39(m,3H),1.34–1.18(m,3H).HRMS(EI)m/z calcd for C
28H
35ClN
4S(M
+)494.2271,found 494.2275.
实施例26 1-(9-(5-(8-氯-10H-苯并[b]吡啶[2,3-e][1,4]噻嗪-10-基)戊基)-3,9-二氮螺环[5.5]十一碳-3-基)乙烷-1-酮(X21)的制备
具体实施步骤同实施例25，不同之处在于原料3-氯丙炔换为乙酰氯，得到黄色油状物X21。
1H NMR(400MHz,Chloroform-d)δ8.00(dd,J＝4.9,1.7Hz,1H),7.24(d,J＝1.6Hz,1H),6.95(d,J＝8.2Hz,1H),6.89(dd,J＝8.2,1.9Hz,1H),6.81–6.76(m,2H),4.06(t,J＝7.0Hz,2H),3.56(t,J＝5.7Hz,2H),3.42(d,J＝7.7Hz,4H),2.95(s,2H),2.74(s,2H),2.09(s,4H),1.83(ddd,J＝24.2,16.8,12.2Hz,7H),1.27(d,J＝12.3Hz,2H).HRMS(EI)m/z calcd for C
27H
35ClN
4OS(M+H)
+499.2220,found 499.2270.
实施例27 8-氯-10-(5-(9-丙基-3,9-二氮螺环[5.5]十一碳-3-基)戊基)-10H苯并[b]吡啶[2,3-e][1,4]噻嗪(X22)的制备
具体实施步骤同实施例25，不同之处在于原料3-氯丙炔换为1-氯丙烷，得到黄色油状物X22。
1H NMR(400MHz,Chloroform-d)δ8.00(dd,J＝4.9,1.7Hz,1H),7.23(d,J＝1.7Hz,1H),6.94(d,J＝8.2Hz,1H),6.88(dd,J＝8.2,1.9Hz,1H),6.80–6.73(m,2H),4.04(t,J＝7.3Hz,2H),2.48(s,6H),1.81(p,J＝7.5Hz,4H),1.63(s,18H),1.46(q,J＝7.8Hz,3H),1.27(d,J＝12.3Hz,2H),0.92(t,J＝7.4Hz,3H).HRMS(EI)m/z calcd for C
28H
39ClN
4S(M
+)498.2584,found 498.2578.
实施例28 8-氯-10-(5-(9-(吡啶-2-基甲基)-3,9-二氮螺环[5.5]十一碳-3-基)戊基)-10H-苯并[b]吡啶[2,3-e][1,4]噻嗪(X23)的制备
具体实施步骤同实施例25，不同之处在于原料3-氯丙炔换为2-氯甲基吡啶，得到黄色油状物X23。
1H NMR(400MHz,Chloroform-d)δ8.57(d,J＝4.4Hz,1H),8.00(d,J＝4.3Hz,1H),7.67(t,J＝7.5Hz,1H),7.44(s,1H),7.21(dd,J＝12.8,7.1Hz,3H),6.94(d,J＝8.2Hz,1H),6.88(d,J＝8.2Hz,1H),6.79(d,J＝9.2Hz,2H),4.05(t,J＝6.8Hz,2H),3.74(m,2H),2.89(m,4H),2.56(m,4H),1.85(dt,J＝14.7,6.9Hz,9H),1.65(s,4H),1.54–1.41(m,3H).HRMS(EI)m/z calcd for C
32H
39ClN
4S(M-H)
-546.2536,found 546.2465.
实施例29 8-氯-10-(5-(9-甲基-3,9-二氮螺环[5.5]十一碳-3-基)戊基)-10H-苯并[b]吡啶[2,3-e][1,4]噻嗪(X24)的制备
向干净的圆底烧瓶中加入800mg X19、1g多聚甲醛、300mg硼氢化钠和10mL三氟乙醇，室温反应3小时，得黄色油状物X24。
1H NMR(400MHz,Chloroform-d)δ8.00(dd,J＝4.9,1.7Hz,1H),7.24(dd,J＝7.5,1.7Hz,1H),6.94(d,J＝8.2Hz,1H),6.88(dd,J＝8.2,1.9Hz,1H),6.81–6.72(m,2H),4.04(t,J＝7.3Hz,2H),2.50(d,J＝18.2Hz,8H),2.39(s,3H),1.81(p,J＝7.4Hz,2H),1.64(t,J＝5.8Hz,10H),1.46(h,J＝7.5,6.4Hz,2H),1.33(t,J＝7.3Hz,2H).HRMS(EI)m/z calcd for C
26H
35ClN
4S(M
+)470.2271,found 470.2263.
实施例30 10-(5-(9-苄基-3,9-二氮螺环[5.5]十一碳-3-基)戊基)-8-氯-10H-苯并[b]吡啶[2,3-e][1,4]噻嗪(X25)的制备
具体实施步骤同实施例25，不同之处在于原料3-氯丙炔换为苄氯，得到黄色油状物X25。
1H NMR(400MHz,Chloroform-d)δ7.99(dd,J＝4.9,1.7Hz,1H),7.31(d,J＝4.3Hz,4H),7.26–7.20(m,2H),6.93(d,J＝8.1Hz,1H),6.87(dd,J＝8.2,1.9Hz,1H),6.80–6.73(m,2H),4.03(t,J＝7.2Hz,2H),3.52(s,2H),2.66–2.46(m,6H),2.40(d,J＝5.7Hz,4H),1.82(q,J＝7.4Hz,2H),1.63(q,J＝7.7,5.6Hz,6H),1.52(t,J＝5.6Hz,4H),1.45(p,J＝7.8Hz,3H).HRMS(EI)m/z calcd for C
32H
39ClN
4S(M
+)546.2584,found 546.2574.
实施例31 8-氯-10-(5-(9-(4-氯苄基)-3,9-二氮螺环[5.5]十一碳-3-基)戊基)-10H-苯并[b]吡啶[2,3-e][1,4]噻嗪(X26)的制备
具体实施步骤同实施例25，不同之处在于原料3-氯丙炔换为4-氯苄氯，得到黄色油状物X26。
1H NMR(400MHz,Chloroform-d)δ8.00(dd,J＝5.1,1.7Hz,1H),7.28(d,J＝2.4Hz,2H),7.26–7.19(m,3H),6.93(d,J＝8.1Hz,1H),6.87(dd,J＝8.3,1.9Hz,1H),6.81–6.72(m,2H),4.03(t,J＝7.3Hz,2H),3.45(s,2H),2.76(s,2H),2.46–2.31(m,8H),1.80(p,J＝7.5Hz,2H),1.47(td,J＝21.4,20.1,10.5Hz,14H).
实施例32 9-(5-(8-(三氟甲基)-10H-苯并[b]吡啶[2,3-e][1,4]噻嗪-10-基)戊基)-3,9-二氮螺环[5.5]十一烷-3-羧酸叔丁酯(X27)的制备
具体实施步骤同实施例7，不同之处在于原料Ⅵ
A换为Ⅵ
C，得到黄色油状物X27。
1H NMR(400MHz,Chloroform-d)δ8.01(dd,J＝4.9,1.7Hz,1H),7.24(dd,J＝7.5,1.7Hz,1H),7.16–7.08(m,2H),6.96(d,J＝1.5Hz,1H),6.79(dd,J＝7.5,4.9Hz,1H),4.10(q,J ＝7.5Hz,2H),3.37(t,J＝5.8Hz,4H),2.70(s,4H),1.83(p,J＝7.4Hz,5H),1.45(s,15H),1.31–1.21(m,2H).HRMS(EI)m/z calcd for C
31H
41F
3N
4O
2S(M
+)590.2902,found 590.2897.
实施例33 9-(5-(8-甲氧基-10H-苯并[b]吡啶[2,3-e][1,4]噻嗪-10-基)戊基)-3,9-二氮螺环[5.5]十一烷-3-羧酸叔丁酯(X28)的制备
具体实施步骤同实施例7，不同之处在于原料Ⅵ
A换为Ⅵ
B，得到黄色油状物X28。
1H NMR(400MHz,Chloroform-d)δ7.99(dd,J＝5.0,1.7Hz,1H),7.25(dd,J＝7.5,1.7Hz,1H),6.94(d,J＝8.3Hz,1H),6.74(dd,J＝7.5,4.9Hz,1H),6.51–6.43(m,2H),4.07(q,J＝7.1Hz,2H),3.78(s,3H),3.36(t,J＝5.8Hz,4H),1.83(p,J＝7.4Hz,2H),1.63(m,6H),1.45(m,15H).HRMS(EI)m/z calcd for C
31H
44N
4O
3S(M
+)552.3134,found 552.3132.
实施例34 9-(5-(10H-苯并[b]吡啶[2,3-e][1,4]噻嗪-10-基)戊基)-3,9-二氮螺环[5.5]十一碳-3-羧酸叔丁酯(X29)的制备
具体实施步骤同实施例7，不同之处在于原料Ⅵ
A换为Ⅵ
D，得到黄色油状物X29。
1H NMR(400MHz,Chloroform-d)δ7.98(dd,J＝4.9,1.7Hz,1H),7.24(dd,J＝7.5,1.7Hz,1H),7.13(ddd,J＝8.4,7.4,1.6Hz,1H),7.04(dd,J＝7.6,1.6Hz,1H),6.90(td,J＝7.5,1.1Hz,1H),6.84(dd,J＝8.2,1.1Hz,1H),6.74(dd,J＝7.4,4.9Hz,1H),4.12–4.03(m,2H),3.41–3.32(m,4H),3.02(q,J＝7.3Hz,2H),1.83(p,J＝7.4Hz,2H),1.66(m,6H),1.45(m,15H),1.36(t,J＝7.3Hz,2H).HRMS(ESI)m/z calcd for C
30H
42N
4O
2S(M+H)
+523.3028,found 523.3075.
实施例35 9-(4-(8-氯-10H-苯并[b]吡啶[2,3-e][1,4]噻嗪-10-基)丁基)-3,9-二氮螺环[5.5]十一烷-3-羧酸叔丁酯(X30)的制备
具体实施步骤同实施例7，不同之处在于原料Ⅵ
A换为Ⅵ
E，得到黄色油状物X30。
1H NMR(600MHz,Chloroform-d)δ8.00(dd,J＝4.9,1.7Hz,1H),7.26–7.23(m,1H),6.95(d,J＝8.2Hz,1H),6.89(dd,J＝8.3,1.9Hz,1H),6.82–6.75(m,2H),4.10(dq,J＝23.5,6.2,5.3Hz,4H),3.36(t,J＝5.8Hz,4H),2.05(m,2H),1.84(m,2H),1.56(m,6H),1.45(m,13H),1.26(t,J＝7.1Hz,2H).HRMS(ESI)m/z calcd for C
29H
39ClN
4O
2S(M+H)
+543.2482,found 543.2520.
实施例36 9-(6-(8-氯-10H-苯并[b]吡啶[2,3-e][1,4]噻嗪-10-基)己基)-3,9-二氮螺环[5.5]十一烷-3-羧酸叔丁酯(X31)的制备
具体实施步骤同实施例7，不同之处在于原料Ⅵ
A换为Ⅵ
F，得到黄色油状物X31。
1H NMR(400MHz,Chloroform-d)δ8.00(dd,J＝4.9,1.7Hz,1H),7.24(dd,J＝7.5,1.7Hz,1H),6.94(d,J＝8.2Hz,1H),6.88(dd,J＝8.2,2.0Hz,1H),6.80–6.74(m,2H),4.03(t,J＝7.3Hz,2H),3.37(dd,J＝7.0,4.5Hz,4H),2.60(m,4H),1.84–1.59(m,8H),1.45(m,19H).HRMS(ESI)m/z calcd for C
31H
43ClN
4O
2S(M+H)
+571.2795,found 571.2843.
实施例37 8-甲氧基-10-(5-(9-甲基-3,9-二氮螺环[5.5]十一碳-3-基)戊基)-10H-苯并[b]吡啶[2,3-e][1,4]噻嗪(X32)的制备
向干净的圆底烧瓶中加入200mg X28、10mL三氟乙酸和10mL二氯甲烷，室温反应2小时后旋干，加入1g多聚甲醛、300mg硼氢化钠和10mL三氟乙醇，室温反应3小时，得黄色油状物X32。
1H NMR(400MHz,Chloroform-d)δ8.00(dd,J＝4.9,1.7Hz,1H),7.27(dd,J＝7.4,1.8Hz,1H),6.96(d,J＝8.4Hz,1H),6.76(dd,J＝7.4,4.9Hz,1H),6.53–6.42(m,2H),4.08(t,J＝7.1Hz,2H),3.80(s,3H),3.13(q,J＝7.3Hz,4H),2.72(d,J＝29.9Hz,8H),2.55(s,3H),1.85(p,J＝7.4Hz,2H),1.47(p,J＝7.4Hz,2H),1.34(t,J＝7.3Hz,6H).HRMS(ESI)m/z calcd for C
27H
38N
4OS(M+H)
+467.2766,found 467.2810.
实施例38(1R，4R)-5-(5-(8-氯-10H-苯并[b]吡啶[2,3-e][1,4]噻嗪-10-基)戊基)-2,5-二氮杂双环[2.2.1]庚烷-2-羧酸叔丁酯(X33)的制备
具体实施步骤同实施例6，不同之处在于原料3-氮螺环[5,5]十一烷换为(1R,4R)-2,5-二氮杂双环[2.2.1]庚烷-2-羧酸叔丁酯，得到黄色油状物X33。
1H NMR(400MHz,Chloroform-d)δ7.92(dd,J＝4.9,1.7Hz,1H),7.14(dd,J＝7.5,1.7Hz,1H),6.84(d,J＝8.2Hz,1H),6.78(dd,J＝8.2,2.0Hz,1H),6.72–6.65(m,2H),4.18(d,J＝50.3Hz,1H),3.96(t,J＝7.3Hz,2H),3.48–3.34(m,2H),3.04(ddd,J＝10.2,7.8,2.2Hz,1H),2.84(ddd,J＝34.1,9.6,2.2Hz,1H),2.58–2.38(m,3H),1.73(q,J＝6.8Hz,3H),1.59(dd,J＝19.4,9.7Hz,1H),1.49–1.39(m,4H),1.38(d,J＝2.0Hz,9H).HRMS(ESI)m/z calcd for C
26H
33ClN
4O
2S(M+H)
+501.2013,found 501.2105.
实施例39 3-(5-(8-氯-10H-苯并[b]吡啶[2,3-e][1,4]噻嗪-10-基)戊基)-3,6-二氮杂环[3.1.1]庚烷-6-羧酸叔丁酯(X34)的制备
具体实施步骤同实施例6，不同之处在于原料3-氮螺环[5,5]十一烷换为6-(叔丁氧羰基)-3,6-二氮杂双环[3.1.1]庚烷，得到黄色油状物X34。
1H NMR(400MHz,Chloroform-d)δ7.93(dd,J＝4.9,1.7Hz,1H),7.16(dd,J＝7.5,1.7Hz,1H),6.86(d,J＝8.1Hz,1H),6.80(dd,J＝8.2,2.0Hz,1H),6.74–6.67(m,2H),3.96(t,J ＝7.4Hz,4H),3.01(s,1H),2.87(s,1H),2.73(s,2H),2.44(t,J＝7.3Hz,2H),2.28(q,J＝6.6Hz,1H),1.72(q,J＝7.4Hz,2H),1.67–1.61(m,1H),1.48(p,J＝7.1Hz,2H),1.39(s,2H),1.37(s,9H).HRMS(ESI)m/z calcd for C
26H
33ClN
4O
2S(M+H)
+501.2013,found 501.2147.
实施例40(1S，4S)-5-(5-(8-氯-10H-苯并[b]吡啶[2,3-e][1,4]噻嗪-10-基)戊基)-2,5-二氮杂双环[2.2.1]庚烷-2-羧酸叔丁酯(X35)的制备
具体实施步骤同实施例6，不同之处在于原料3-氮螺环[5,5]十一烷换为(1S,4S)-2,5-二氮杂双环[2.2.1]庚烷-2-甲酸叔丁酯，得到黄色油状物X35。
1H NMR(400MHz,Chloroform-d)δ7.93(dd,J＝4.9,1.6Hz,1H),7.17(dd,J＝7.5,1.7Hz,1H),6.87(d,J＝8.1Hz,1H),6.80(dd,J＝8.2,1.9Hz,1H),6.74–6.67(m,2H),4.21(d,J＝50.8Hz,1H),3.97(t,J＝7.3Hz,2H),3.45(t,J＝12.4Hz,2H),3.06(t,J＝8.8Hz,1H),2.89(d,J＝37.7Hz,1H),2.56–2.35(m,3H),1.74(dd,J＝14.9,7.6Hz,3H),1.66–1.59(m,1H),1.51–1.39(m,4H),1.38(d,J＝2.0Hz,9H).HRMS(ESI)m/z calcd for C
26H
33ClN
4O
2S(M+H)
+501.2013,found 501.2129.
实施例41本发明化合物对子宫内膜癌细胞的增殖抑制作用
本发明通过CCK-8实验评价10-取代-1-氮杂吩噻嗪衍生物对子宫内膜癌细胞的增殖抑制活性。
1、实验材料和方法
子宫内膜癌细胞ISK和KLE购自于美国模式菌种收集中心(ATCC)；磷酸盐缓冲盐溶液(PBS)购自于Bio-channel公司；DMEM/F12培养基购自于Biosharp公司；胎牛血清(FBS)和胰蛋白酶购自于Gibco公司；CCK-8购自于碧云天生物科技有限公司。
ISK和KLE细胞用DMEM/F12(含10％胎牛血清，1％青霉素/链霉素)培养基，并置于37℃，5％CO
2的培养箱中培养。待子宫内膜癌细胞基本长满细胞培养皿(10cm)后，用胰蛋白酶将细胞消化下来，并以5000个/孔的细胞密度种到96孔板中，每孔100μL。培养过夜，待细胞贴壁后，分别加入含不同浓度衍生物的DMEM/F12培养基，每孔200μL，每组设3个复孔。在细胞培养箱中孵育48h。随后去除培养基，每孔加入100μL含10％CCK-8的无血清培养基，在培养箱中37℃孵育1h后，使用Bio-Tek多功能酶标仪检测在450nm处的吸光值A，计算抑制率和IC
50值。抑制率计算公式：细胞抑制率％＝[1-(给药组A值-空白组A值)/(对照组A值-空白组A值)]×100％，IC
50值通过Graphpad Prism 8.0软件拟合。
2、实验结果
10-取代-1-氮杂吩噻嗪衍生物对子宫内膜癌细胞的增殖抑制活性如表1和表2所示， 结果表明，衍生物对子宫内膜癌细胞ISK和KLE的增殖均具有显著的抑制作用。
表1 10-取代-1-氮杂吩噻嗪类衍生物对ISK细胞的增殖抑制活性结果
表2 10-取代-1-氮杂吩噻嗪类衍生物对KLE细胞的增殖抑制活性结果
实施例42本发明化合物对子宫内膜癌细胞克隆形成的抑制作用
本发明在细胞水平上通过平皿克隆形成实验测试化合物X32对子宫内膜癌细胞ISK和KLE克隆形成能力的影响。研究结果表明，化合物X32能够浓度依赖性地抑制子宫内膜癌细胞ISK和KLE的克隆形成。
1、实验材料和方法
0.5％的结晶紫染液购自于碧云天生物科技有限公司；甲醇为实验室常用试剂，商业购买，未经任何处理。其余实验材料来源同实施例41。取对数生长期的EC细胞，用胰蛋白酶消化下来制备成单细胞混悬液，以每孔约1000个细胞的密度接种至6孔板，过夜培养。待细胞贴壁后，分成4组，分别为对照组和不同的给药组，每组设3个复孔。给药组用含不同浓度药物的DMEM/F12培养基2mL，对照组加不含药物的培养基，培养48h，之后换成无药的培养基继续培养8天左右。待细胞长成肉眼可见的细胞群落后，置于冰上，用预冷的PBS清洗细胞两次，每次3min。然后用预冷的甲醇，于-20℃固定细胞10min。吸除甲醇，加入结晶紫染液1mL，染色30min。移除结晶紫染液，清水清洗至染液被洗脱完毕。倒扣6孔板待其晾干，用凝胶成像仪拍照，Image J软件手动计数，统计各个孔的克隆形成数。
2、实验结果
实验结果如图1所示，图中Ctrl为对照组，照片中的每一个黑点表示一个细胞群落。结果表明，对于ISK细胞，与Ctrl相比，给药组的细胞群落数量减少，且随着化合物X32浓度的增加而明显减少，尤其是化合物X32的2μM组，说明化合物X32对ISK细胞的克隆形成具有抑制作用，并且能够浓度依赖性地抑制子宫内膜癌细胞ISK的克隆形成。对于KLE细胞，与对照组相比，给药组的细胞群落数量也有所减少，且随着化合物X32浓度的增加而明显减少，说明化合物X32对KLE细胞的克隆形成具有抑制作用，并且能够浓度依赖性地抑制子宫内膜癌细胞KLE的克隆形成。柱状图纵坐标表示各组细胞群落的数目，数据显著性差异采用One-way ANOVA法分析(Graphpad Prism 8.0软件)。
实施例43本发明化合物对子宫内膜癌细胞迁移能力的抑制作用
本发明在细胞水平上通过Transwell实验测试了化合物X32对子宫内膜癌细胞ISK和KLE迁移能力的影响。研究结果表明，X32能够抑制子宫内膜癌细胞ISK和KLE迁移。
1、实验材料和方法
Transwell小室购自于Costar公司；多聚甲醛为实验室常用试剂，商业购买，未经任何处理，其余实验材料来源同实施例41。取对数生长期的EC细胞，用胰蛋白酶消化下来，使用不含血清的DMEM/F12培养基制备成单细胞混悬液，以每孔约10万个细胞的密度接种至Transwell小室上方。小室下方加入600μL含20％FBS的DMEM/F12培养基，注意避免气泡产生。分成4组，分别为对照组和不同的给药组，每组设3个复孔。给药组的上室加入含不同药物的无血清DMEM/F12培养基150μL，对照组上室加入无药物无血清的DMEM/F12培养基150μL。置于37℃，5％CO
2的培养箱培养24h。随后用镊子小心取出小室，吸干上室液体，移到预先加入约800μL预冷PBS的24孔板中，清洗2次，每次5 min。取出小室，移到预先加入约800μL多聚甲醛溶液的24孔板中，室温固定30min。取出小室，吸干上室固定液，移到预先加入约800μL结晶紫染液的24孔板中，室温染色30min。轻轻用清水冲洗数次，用湿棉棒小心擦去上室膜表面上的细胞。200倍显微镜下随机取5个视野拍照，Image J软件手动计数，统计各个视野下的细胞数。
2、实验结果
结果如图2所示，图中Ctrl为对照组，照片中的每一个点表示一个穿过小室的细胞。结果表明，在ISK和KLE细胞中，与Ctrl组相比，给药组穿过小室的细胞数量减少，且随着化合物X32浓度的增加而明显减少，尤其是高剂量组，只有少量细胞穿过，说明化合物X32具有抑制ISK和KLE细胞迁移的能力，并且能够浓度依赖性地抑制子宫内膜癌细胞的迁移。柱状图纵坐标表示各组穿过小室细胞数目，数据显著性差异采用One-way ANOVA法分析(Graphpad Prism8.0软件)。
实施例44本发明化合物对子宫内膜癌细胞凋亡的影响
本发明在细胞水平上采用Annexin V-FITC/PI细胞凋亡检测试剂盒测试化合物X32对子宫内膜癌细胞ISK和KLE凋亡的影响。研究结果表明，化合物X32能够诱导子宫内膜癌细胞ISK和KLE凋亡。
1.实验材料和方法
Annexin V-FITC/PI细胞凋亡检测试剂盒购自于碧云天生物科技有限公司，其中Annexin V-FITC结合液、Annexin V-FITC、碘化丙啶(PI)均为试剂盒中试剂。其余实验材料来源同实施例41。取对数生长期的EC细胞，用胰蛋白酶消化下来制备成单细胞混悬液，以每孔约12万个细胞的密度接种至6孔板，过夜培养。待细胞贴壁后，分成4组，分别为对照组和不同的给药组，每组设3个复孔。给药组加入含不同浓度衍生物的DMEM/F12培养基2mL，对照组加入无药物DMEM/F12培养基2mL。在37℃，5％CO
2的培养箱孵育48h。随后将细胞培养液吸出至10ml离心管内，PBS清洗贴壁细胞一次，加入300μL胰酶消化细胞2min，将细胞轻轻吹打下来，转移到相应离心管内，1000rpm离心5min，弃上清，收集细胞，用PBS轻轻重悬细胞并计数。取5-10万重悬的细胞，1000rpm离心5min，弃上清，加入195μL Annexin V-FITC结合液轻轻重悬细胞，加入5μL Annexin V-FITC和10μL碘化丙啶(PI)染色液，轻轻混匀。室温避光孵育20min，立即用Beckman Coulter(cytoFLEX LX)流式细胞仪检测。
2、实验结果
结果如图3所示，图中Ctrl为对照组，在凋亡示意图中的第一象限为晚凋细胞，第四象限为早凋细胞，凋亡比例为第一、四象限比例之和。与对照组相比，化合物X32能够显著诱导ISK和KLE细胞凋亡，并且具有浓度依赖性。柱状图纵坐标表示各组细胞凋亡比例，数据显著性差异采用One-way ANOVA法分析(Graphpad Prism8.0软件)。
实施例45本发明化合物对小鼠中枢神经***的影响
本发明通过转棒试验测试了化合物X32对小鼠中枢神经***的影响，即锥体外系副作用。研究结果表明，化合物X32的中枢神经***的副作用较低，100mg/kg和50mg/kg给 药剂量基本不影响小鼠抓握运动能力，无锥体外系副作用。
1、实验材料和方法
实验动物选择7-8周龄的雌性C57BL/6裸鼠，购自上海斯莱克有限公司；顺铂(DDP)来源于实验室老药库。化合物配制方法是称取一定量的化合物，溶于生理盐水中，对照组给予相应溶剂。化合物给药前现配现用。
小鼠随机分为4组：对照组、阳性药氯丙嗪5mg/kg、X32 50mg/kg、X32 100mg/kg。每组12只。先提前三天训练小鼠以适应转棒运动：每天以35rpm/min的转速训练小鼠运动3min。第四天在腹腔注射给药0.1mL 1小时后(对照组注射生理盐水0.1mL)，在35rpm/min的转速下，记录小鼠5min内在转棒上坚持的时间。
2、实验结果
实验结果如图4所示，图中Vehicle为对照组，纵坐标代表小鼠掉落时间，每个点代表一只小鼠掉落时间。可以看出，化合物X32 100mg/kg和50mg/kg给药剂量均对小鼠抓握运动能力无明显影响，小鼠随棒转动的平均时间为分别为255s和243s，和对照组无显著性差异；氯丙嗪5mg/kg给药剂量对小鼠抓握运动能力有很大影响，小鼠随棒转动的平均时间为142s(p＜0.001)。实验结果表明，X32 100mg/kg和50mg/kg给药剂量基本不影响小鼠抓握运动能力。数据显著性差异采用One-way ANOVA法分析(Graphpad Prism8.0软件)。
实施例46本发明化合物对子宫内膜癌荷瘤小鼠皮下移植瘤生长的抑制作用
本发明通过裸鼠体内皮下成瘤实验测试了化合物X01对子宫内膜癌细胞(KLE)移植瘤生长的影响。研究结果表明，化合物X01能够显著抑制小鼠皮下KLE细胞移植瘤的生长。
1、实验材料和方法
实验动物选择5-6周龄的SPF级的雌性BALB/C裸鼠，购自上海斯莱克动物实验有限公司；顺铂(DDP)来源于实验室老药库。化合物配制方法是称取一定量的化合物，溶于生理盐中稀释成所需浓度，对照组给予相应溶剂。化合物给药前现配现用。
首先在5-6周龄的裸鼠右侧腋下皮下植入KLE细胞，每只小鼠约植入500万个细胞。待肿瘤长至800-1000mm
3后处死小鼠，再将肿瘤组织切成大小均匀的肿瘤组织块，通过手术移植到新的5-6周龄裸鼠右侧腋下皮下。待新长出的肿瘤体积达到平均300-400mm
3时，将小鼠随机分4组：对照组、阳性药DDP 2mg/kg、X01 2mg/kg给药组、X01 5mg/kg给药组、氯丙嗪5mg/kg组。按不同的药物浓度腹腔注射0.1mL，对照组腹腔注射生理盐水0.1mL，每天称量小鼠体重，每天给药。连续给药2周后，处死小鼠，剥离肿瘤，拍照。解剖当天用游标卡尺测量肿瘤长L(mm)和宽W(mm)，肿瘤体积计算公式V(mm
3)＝0.5×L(mm)×W(mm)
2。
2、实验结果
实验结果如图5所示，图中Vehicle为对照组。其中图5中A为小鼠体重随给药时间的变化曲线，横坐标为给药天数，纵坐标为小鼠体重，从图中可以看到，X01给药组体重平稳，顺铂DDP组体重有明显下降。图5中B、C、D可以看出给药结束后，与对照组相 比，化合物X01给药组的肿瘤生长均受到抑制，X01 2mg/kg和X01 5mg/kg均能显著抑制小鼠肿瘤的生长，且与阳性药顺铂组效果相当甚至略优于顺铂。数据显著性差异采用One-way ANOVA法分析(Graphpad Prism8.0软件)。本实验证明化合物X01能够抑制小鼠皮下KLE细胞移植瘤的生长且对体重没有影响，其药效与阳性药顺铂相当，毒性小于顺铂。
以上所述仅是本发明的较佳实施例而已，并非对本发明作任何形式上的限制，虽然本发明已以较佳实施例揭露如上，然而并非用以限定本发明，任何熟悉本专利的技术人员在不脱离本发明技术方案范围内，当可利用上述提示的技术内容作出些许更动或修饰为等同变化的等效实施例，但凡是未脱离本发明技术方案的内容，依据本发明的技术实质对以上实施例所作的任何简单修改、等同变化与修饰，均仍属于本发明方案的范围内。
Claims (13)
- 一种式I所示化合物、或其立体异构体或药学上可接受的盐，其中，n为2、3、4、5或6；R 1为H、羟基、卤素、C 1-C 6烷基、C 1-C 6卤代烷基、C 1-C 6烷氧基、硝基、亚硝基、氨基、甲酰基、乙酰基或氰基；R 2为取代或未取代的6-14元杂环基，所述杂环基含有选自下组的1、2、3或4个杂原子：N、O、S；所述取代是指具有一个或多个选自下组的取代基：-COOC 1-C 6烷基、-C 1-C 6亚烷基C 6-C 10芳基、氧代(＝O)、C 1-C 6烷基、C 1-C 6卤代烷基、C 2-C 6烯基、C 2-C 6炔基、-COC 1-C 6烷基、-C 1-C 6亚烷基5-7元杂芳基、C 6-C 10芳基、5-7元杂芳基、-C 1-C 6亚烷基卤代C 6-C 10芳基、C 3-C 8环烷基。
- 如权利要求1所述的化合物，其特征在于，R 1为H、羟基、F、Cl、Br、甲基、乙基、正丙基、异丙基、C 1-C 4氟代烷基、甲氧基、乙氧基。
- 如权利要求1所述的化合物，其特征在于，R 2为式I-2或者I-3，A 1、A 2、A 3、A 4各自独立地选自：N、O、S、-CO(CH 2) p-、-(CH 2) m-、-(CH 2) mO-、-(CH 2) mS-；m、p各自独立地为0、1、2或3；X为CH、N或O；n 1、n 2、n 3、n 4各自独立地为0、1、2或3；R 3为H、-COOC 1-C 6烷基、-C 1-C 6亚烷基C 6-C 10芳基、C 1-C 6烷基、C 1-C 6卤代烷基、C 2-C 6烯基、C 2-C 6炔基、-COC 1-C 6烷基、-C 1-C 6亚烷基5-7元杂芳基、C 6-C 10芳基、5-7元杂芳基、-C 1-C 6亚烷基卤代C 6-C 10芳基、C 3-C 8环烷基。
- 如权利要求1所述的化合物，其特征在于，R 3为H、叔丁氧羰基、C 1-C 4烷基、氯代苄基、苄基、-CH 2-6元含氮杂芳基、-COC 1-C 4烷基或C 2-C 4炔基。
- 如权利要求1所述的化合物，其特征在于，所述化合物选自下组：
- 一种药物组合物，其特征在于，所述药物组合物包括：(1)如权利要求1所述的化合物、或其药学上可接受的盐、或其立体异构体；和(2)药学上可接受的载体。
- 如权利要求6所述的药物组合物，其特征在于，所述药物组合物还包括其他药学上可接受的成分为抗子宫内膜癌药物。
- 如权利要求7所述的药物组合物，其特征在于，所述抗子宫内膜癌药物为孕激素。
- 如权利要求8所述的药物组合物，其特征在于，所述孕激素为醋酸甲地孕酮、酸酸甲羟孕酮或己酸孕酮中的一种或两种以上的组合。
- 如权利要求6所述的药物组合物，其特征在于，所述药物组合物为注射剂、片剂、胶囊剂、丸剂、悬浮剂或乳剂。
- 如权利要求6所述的药物组合物，其特征在于，所述药物组合物为口服剂型、经皮剂型、静脉或肌肉注射剂型。
- 如权利要求1所述的化合物或其立体异构体，或其药学上可接受的盐或如权利要求6所述的药物组合物的用途，其特征在于，用于制备治疗和/或预防子宫内膜癌的药物。
- 如权利要求1所述的化合物或其立体异构体，或其药学上可接受的盐的制备方法，其特征在于，包括步骤：
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2021/123627 WO2023060489A1 (zh) | 2021-10-13 | 2021-10-13 | 10-取代-1-氮杂吩噻嗪衍生物及其应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117715907A true CN117715907A (zh) | 2024-03-15 |
Family
ID=85987204
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202180098067.1A Pending CN117715907A (zh) | 2021-10-13 | 2021-10-13 | 10-取代-1-氮杂吩噻嗪衍生物及其应用 |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN117715907A (zh) |
| WO (1) | WO2023060489A1 (zh) |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2974139A (en) * | 1954-10-02 | 1961-03-07 | Degussa | Thiophenylpyridyl amines |
| US2943086A (en) * | 1955-07-26 | 1960-06-28 | Olin Mathieson | Pharmaceutical compounds |
| US3106561A (en) * | 1955-07-26 | 1963-10-08 | Olin Mathieson | Certain 2-(2'-lower alkanoyl-amidophenylthio)-3-nitropyridines |
| GB814065A (en) * | 1957-02-13 | 1959-05-27 | Smith Kline French Lab | Substituted phenoselenazine compounds |
| GB893284A (en) * | 1957-12-03 | 1962-04-04 | Degussa | Process for the production of piperazino-alkyl-4-azaphenthiazine |
| DE1160442B (de) * | 1959-03-18 | 1964-01-02 | Degussa | Verfahren zur Herstellung von 3-Trifluormethylphenthiazinen |
| DE1209120B (de) * | 1963-02-05 | 1966-01-20 | Degussa | Verfahren zur Herstellung von 2-Chlor-4-azaphenthiazinen |
-
2021
- 2021-10-13 CN CN202180098067.1A patent/CN117715907A/zh active Pending
- 2021-10-13 WO PCT/CN2021/123627 patent/WO2023060489A1/zh active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023060489A1 (zh) | 2023-04-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107428758B (zh) | 丙烯酸类衍生物、其制备方法及其在医药上的用途 | |
| CN105916848B (zh) | 激酶抑制剂及其用途 | |
| WO2020156285A1 (zh) | 一种苯并吡啶酮杂环化合物及其用途 | |
| CN108329311B (zh) | 作为选择性***受体下调剂的三环类化合物及其应用 | |
| US10208042B1 (en) | Multi-kinase inhibitor compound, and crystal form and use thereof | |
| EP4031547A1 (en) | Plasma kallikrein inhibitors and uses thereof | |
| US20080045501A1 (en) | Pyridobenzazepine compounds and methods for inhibiting mitotic progression | |
| TW201141857A (en) | Analogues for the treatment or prevention of flavivirus infections | |
| TWI750403B (zh) | 成纖維細胞生長因子受體抑制劑、含有其的藥物製劑及其用途 | |
| CA3061209A1 (en) | Compound used as autophagy regulator, and preparation method therefor and uses thereof | |
| JP6860237B2 (ja) | インドールアミン２，３−ジオキシゲナーゼ阻害剤及び適用 | |
| WO2023131277A1 (zh) | Nlrp3炎症小体抑制剂及其应用 | |
| JP2022541436A (ja) | Ｅｅｄ阻害剤としてのイミダゾピリミジンおよびその使用 | |
| CN113387962A (zh) | 吡唑并[3,4-d]嘧啶-3-酮衍生物、其药物组合物及应用 | |
| CN104829596A (zh) | 吡咯取代吲哚酮类衍生物、其制备方法、包含该衍生物的组合物、及其用途 | |
| CN109923115A (zh) | 咪唑并[1’,2’:1,6]吡啶并[2,3-d]嘧啶类化合物作为蛋白激酶抑制剂 | |
| CN117715907A (zh) | 10-取代-1-氮杂吩噻嗪衍生物及其应用 | |
| CN111978317A (zh) | 咪唑并吡啶类mnk1/mnk2激酶抑制剂及其制备方法和应用 | |
| CN104230960B (zh) | 四并环类间变性淋巴瘤激酶抑制剂 | |
| CN110903289A (zh) | 嘌呤-氨甲基-吡啶酮衍生物及其制备方法和用途 | |
| WO2023164940A1 (zh) | 氮杂吩噻嗪类化合物及其在制备治疗子宫内膜癌的药物中的应用 | |
| TW202237101A (zh) | Ｃｔｌａ－４小分子降解劑及其應用 | |
| WO2024094185A1 (zh) | Nlrp3炎症小体抑制剂及其应用 | |
| WO2024039861A1 (en) | 2,3,4,9-tetrahydro-1h-pyrido[3,4-b]indole derivatives as estrogen receptor modulators for the treatment of cancer | |
| WO2024140736A1 (zh) | 三肽环氧酮化合物、药物组合物及其制备方法和用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |